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Abstract 
Ischaemic cardiovascular diseases are the leading cause of death worldwide. 
Therapeutic angiogenesis provides a valuable tool to treat these conditions by 
stimulating the growth of new blood vessels in the ischaemic tissue. The pro-angiogenic 
factor VEGF is the most potent inducer of angiogenesis, and exogenous delivery of 
VEGF has been a key element of therapeutic strategies. Unfortunately, VEGF-based 
pro-angiogenic procedures have produced only limited patient benefit. Failure to restore 
efficient VEGF activity remains a major problem.  
VEGF-mediated activation of the calcineurin/NFAT signalling pathway has been 
identified as a crucial regulator of angiogenesis. Our laboratory has recently shown a 
novel role for the plasma membrane calcium ATPase 4 (PMCA4) protein as a negative 
regulator of VEGF-induced angiogenesis via interaction with calcineurin. The recent 
identification of aurintricarboxylic acid (ATA) as a selective inhibitor of PMCA4 prompted 
us to hypothesise that inhibition of PMCA4 with ATA should enhance VEGF-induced 
angiogenesis. 
Here, we show that treatment of endothelial cells with nanomolar concentrations of ATA 
notably enhances calcineurin/NFAT signalling by disrupting the PMCA4/calcineurin 
interaction.  ATA mediated inhibition of PMCA4 results in a significant increase in 
endothelial cell motility and in vitro and in vivo blood vessel formation. Low 
concentrations of ATA do not have any deleterious effects on the viability of endothelial 
cells or zebrafish embryonic development. However, high ATA concentrations impaired 
endothelial cell viability, and were associated with toxicity in zebrafish embryos. 
This study highlights the potential of targeting PMCA4 to improve VEGF-based pro-
angiogenic therapeutic strategies. This goal will require the development of refined 
versions of ATA without associated toxicity, or the identification of novel PMCA4 
inhibitors.  
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1.1 Angiogenesis  
Angiogenesis is a biological process by which new blood vessels are formed from pre-
existing ones (Carmeliet and Jain, 2011). It is a fundamental process that occurs both in 
physiological and pathological settings. In normal conditions, angiogenesis is essential 
for embryogenesis, organ growth, menstrual cycle, bone formation and tissue repair 
(Carmeliet and Jain, 2011). This physiological process is tightly regulated, involving the 
participation of a number of pro- and anti-angiogenic mediators (Carmeliet, 2005). An 
imbalance in the production of these angiogenic activators or inhibitors, results in 
aberrant blood vessel formation in several human diseases such as tumour growth and 
metastasis, diabetic retinopathy, ischaemic disorders, rheumatoid arthritis, and age-
related macular degeneration (Carmeliet and Jain, 2000). As we will see in the following 
sections, among all the factors implicated in angiogenesis progression, vascular 
endothelial growth factor (VEGF) and its receptor VEGF-R have been identified as key 
regulators of both physiological and pathological angiogenesis (Takahashi and Shibuya, 
2005). 
1.1.1 Physiological angiogenesis 
1.1.1a Embryonic Development 
A key aspect in the development of any tissue or organ is the formation of a proper 
vascular network that transports oxygen and nutrients to the developing organs (Patel-
Hett and D’Amore, 2011). Although this is the main function of the vascularity, it also 
has many other physiological tasks. Vasculogenesis is the process through which a 
primary vascular network is formed in the embryo (Goldie et al., 2008). Vasculogenesis 
involves the differentiation of precursor cells called hemangioblasts into endothelial cells 
(Patan, 2000). Angiogenesis then extends the primitive vascular network through 
remodelling of the primary vessels by forming new vessels through intussusceptive 
angiogenesis or vascular sprouting. In the case of intussusceptive angiogenesis a pre-
3 
 
existing lumen is divided into two by tissue insertion (Patan, 2000) (Figure 1.1). In 
sprouting, the vessel segments go through a process, involving basement membrane 
degradation, endothelial cell proliferation, and solid sprouts formation (Patan, 2000) 
(Figure 1.1).  Angiogenesis begins at embryonic day E9.5 (Patel-Hett and D’Amore, 
2011). The importance of this process in embryo development is well demonstrated, as 
attenuation of vascular formation and yolk sac development by inhibition of 
angiogenesis in vivo prevents embryo growth (Klauber et al, 1997). As we have 
mentioned before, VEGF plays an essential role in embryonic development. Lack of this 
pro-angiogenic factor results in embryonic lethality (Carmeliet et al, 1996; Ferrara et al, 
1996) even in heterozygous animals (Hiratsuka et al., 2004). 
 
 
 
Figure 1.1 Diagrammatic description of the difference between intussusceptive and 
sprouting angiogenesis. In intussusceptive angiogenesis a new blood vessel is created by 
splitting of an existing blood vessel into two. In sprouting angiogenesis new blood vessels 
branch out from pre-existing ones. 
 
1.1.b Wound healing    
Wound healing is divided into four predictable phases: haemostasis (blood clotting), 
inflammation, proliferation (tissue growth), and extracellular matrix formation and 
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remodelling (maturation). Angiogenesis normally occurs during the proliferation phase 
(Greaves et al, 2013) which occurs between days 3 and 20 after wound occurrence 
(Bauer et al, 2005). The angiogenic process is essential for delivering oxygen and 
nutrients to the wounded area. It will also restore the capillaries that have been injured 
(Greaves et al, 2013), and helps to remove debris from the site of injury (Nissen et al, 
1998). A significant increase in the amount of VEGF present in the area of wound is 
detected between 3 and 7 days after initial wound occurrence, indicating the importance 
of this factor in the healing process (Nissen et al, 1998). The VEGF present in the 
wound can be produced from many cell types such as keratinocytes, platelets, 
macrophages, neutrophils, endothelial cells, fibroblasts, or smooth muscle cells 
(Greaves et al., 2013)   
1.1.1c Menstrual Cycle 
The menstrual cycle is comprised of three main phases; the menstruation phase, the 
proliferative phase and the secretory phase. During the menstrual cycle angiogenesis is 
an essential process for the restoration of the remaining layer of the endometrium and 
the growth of blood spiral arterioles (Demir et al, 2010; Maas et al, 2001; Shifren et al, 
1996). Human endometrial fragments in early proliferative and late secretory phases 
show a significant increment in the number of vessels present in the endometrium, 
confirming a requirement for angiogenesis at these specific time points in the menstrual 
cycle (Maas et al, 2001). Furthermore, elevated levels of VEGF mRNA expression in 
human endometrium during the proliferative phase reinforce the relevance of VEGF-
driven angiogenesis as an essential process for the physiology of the endometrium 
during the menstrual cycle (Shifren et al, 1996). 
1.1.2 Pathological angiogenesis  
Pathological angiogenesis is the result of an imbalance in the production of pro- and 
anti-angiogenic factors that leads to either insufficient or excessive blood vessel 
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formation in a wide variety of human diseases (Carmeliet, 2005). Unlike physiological 
angiogenesis, pathological angiogenesis results in the formation of abnormal, leaky 
blood vessels. 
1.1.2a Pathologies associated with excessive angiogenesis  
1.1.2a(i) Rheumatoid Arthritis   
Rheumatoid arthritis (RA) is a complex chronic disorder characterised by distinct 
autoimmune, inflammatory and fibrovascular components which lead to synovial 
proliferation and joint destruction (Stupack et al., 1999). Sone et al, 2001 reported that 
the severity of the disease positively correlates with increments in the amount of VEGF 
in the synovium (Sone et al, 2001). During RA the synovium undergoes inflammation 
and increments in mass, generating a hypoxic environment that triggers upregulation of 
VEGF gene expression and the subsequent increase in angiogenesis (Paleolog, 2002). 
The newly formed blood vessels not only transport oxygen and nutrients to support the 
proliferation of synovial cells, but also localise inflammatory cells in the area leading to 
inflammation of the synovium (Marrelli et al, 2011). 
1.1.2a(ii) Psoriasis  
Psoriasis is a common chronic skin disorder characterized by epidermal hyperplasia, 
cutaneous inflammation and increased angiogenesis (Singh et al., 2013). In particular, 
microvessels of the papillary dermis are elongated and dilated, resulting in increased 
permeability (Detmar et al., 1994). VEGF and VEGF receptors VEGFR-1 and 2 have 
been identified as major epidermis-derived vessel-specific growth factors strongly up-
regulated in the hyperplastic epidermis (Li et al., 2014). This fact highlights the link 
between augmented angiogenesis and the increased demand of nutrients and oxygen 
at hyperplastic sites that characterise psoriasis lesions (Detmar et al., 1994).  
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1.1.2a(iii) Retinopathies  
Several studies have suggested a role for angiogenesis in retinopathy (Aiello et al., 
1994; Adamis et al., 1994). According to these studies, elevated levels of VEGF in the 
vitreous and aqueous fluid in the retina of retinopathy patients lead to abnormal 
formation of new and highly permeable blood vessels in the eye of the patient (Cheung 
et al., 2010).  
Choroidal neovascularisation in wet age-related macular degeneration (AMD) is a 
severe ocular complication associated with abnormal vessel growth in the retina 
(Kourlas and Abrams, 2007; Zhou and Wang, 2006) that causes vessel leaking and 
haemorrhage, and results in retinal pigment epithelium detachment (Kourlas and 
Abrams, 2007). AMD is the most common cause of irreversible sight loss in elderly 
patients (Zhou and Wang, 2006). Cheung et al, 2010 showed that the expression of 
VEGF is elevated in retinal endothelial cells and pericytes of diabetic retinopathy 
patients due to the presence of a hypoxic environment within the eye (Cheung et al, 
2010; Adamis et al, 1994). It is thought that elevated levels of glucose in the blood of 
the patient cause apoptosis of endothelial cells in the choroid leading to vessel 
rarefaction and generating a hypoxic micro-environment in the eye that, ironically, 
promotes the formation of new, leaky blood vessels (Shin et al., 2014). Haemorrhage 
and fluid leaking from this abnormal vasculature lead to an increase in ocular fluid that 
elevates intraocular pressure and severely damages the patient’s eye (Kourlas and 
Abrams, 2007).  
1.1.2a(iv) Endometriosis 
Endometriosis is a chronic inflammatory disease characterized by the presence and 
growth of endometrial tissue outside the uterine cavity (Hull et al, 2003). Angiogenesis 
plays an essential role in the development of a vascular supply and growth of 
endometric lesions (Hull et al, 2003). Increased level of VEGF expression has been 
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demonstrated in the peritoneal fluid of women suffering endometriosis and this 
correlates with the severity of the disease (Shifren et al, 1996).  
1.1.2a(v) Tumour Angiogenesis 
When a tumour reaches a size of 1-2mm, it requires high levels of nutrients and oxygen 
so the tumoral cells can live and keep growing (Bergers and Benjamin, 2003). This 
supply of nutrients along with oxygen is facilitated by angiogenesis (Papetti and 
Herman, 2002). Angiogenesis is also reported to be one of the key reasons for the 
metastatic spread of tumours (Jain, 2005). Tumour vessels are reported to be leaky, 
disorderly, dilated and often to have dead ends resulting in reduced blood flow to the 
tumour (Bergers and Benjamin, 2003). In tumours, pericytes also appear to be more 
loosely attached to the vasculature leading to incomplete vessel maturation (Bergers 
and Benjamin, 2003). Tumours that are actively proliferating are reported to introduce 
additional stress on the vasculature, leading to constricted blood flow into tumours (Jain, 
2005). Elevated levels of VEGF are linked to increase in microvessel density and 
decrease in the survival rate of patients (Toi et al, 1994) indicating that as in other 
aspects of physiological and pathological angiogenesis, the axis VEGF-VEGFR plays 
also a pivotal role in the progression of angiogenesis in tumours (Chen et al., 2012).   
1.1.2b Pathologies associated with insufficient angiogenesis 
1.1.2b(i) Ischaemic heart disease  
Ischaemic heart disease is a condition that affects the supply of blood to the heart. The 
coronary arteries become narrowed or blocked due to gradual deposition of fatty 
material on their walls. This condition is known as atherosclerosis. Progression of the 
disease is associated with the growth and/or episodic rupture of atherosclerosis lesions 
leading to narrowing or occlusion of major coronary arteries and resulting in insufficient 
coronary perfusion to match the myocardial oxygen demand (Koerselman et al., 2003). 
It is well established that cardiac ischaemia activates vascular regrowth responses in 
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the heart to protect the myocardial tissue against the ischaemic condition by sprouting 
existing capillaries (angiogenesis) and by developing collateral vessels (arteriogenesis) 
in the occluded coronary artery that bypass the area of stenosis or occlusion (Seiler, 
2010). Unfortunately, patients with similar degrees of coronary stenosis show a marked 
variability in the development of new capillary and collateral artery vessels, and 
reperfusion of the ischaemic heart is not efficient in many cases (Hansen et al., 1989). 
Moreover, formation of new blood vessels is significantly impaired in patients with type 2 
diabetes, metabolic syndrome, and severe atherosclerosis (Rocic et al., 2012; Turgut et 
al., 2009).  
1.1.2b(ii) Peripheral arterial disease   
Peripheral arterial disease (PAD) is mainly caused by occlusive atherosclerosis in a 
vascular bed other than the heart or the brain. PAD most commonly affects the lower 
extremity, but other arteries may also be involved (Brostow et al., 2012). Critical limb 
ischaemia (CLI) is considered the most-severe clinical manifestation of PAD (Annex, 
2013). The arterial narrowing or obstruction of arteries in the lower limbs impairs blood 
flow to the lower extremities consequently causing limb pain, ulcers, gangrene and in 
severe cases amputation (below the knee or higher) (Annex, 2013).  
1.1.2b(iii) Stroke 
Stroke is a devastating disease caused by occlusion of a cerebral artery followed by 
disturbances in blood supply through microvessels to the brain tissue leading to severe 
brain damage (Seto et al., 2016). Therapeutic approaches for patients with acute 
ischaemic stroke focus on neuroprotection, thrombolysis and surgical clot removal. 
Recent studies have shown that new vessel formation after ischaemic stroke not only 
supplies blood to the ischaemic tissue, but also promotes neurogenesis and improves 
neurological functions in both animal models and patients (Seto et al., 2016). Issa et al., 
1999 reported that VEGF and its receptors were up-regulated in human brain tissue 
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after ischaemic stroke (Issa et al., 1999). Several studies in animal models proposed 
that an intra-cerebroventricular injection of VEGF reduced neurological deficits after 
focal cerebral ischaemia (Issa et al., 1999). Unfortunately, VEGF treatment was 
reported to lead to blood-brain barrier (BBB) leakage, brain edema, vasodilation and 
aberrant systemic hemodynamics (Issa et al., 1999). 
 
Figure 1.2 Schematic diagram describing major pathological disorders in humans 
associated with angiogenesis deregulation. 
 
1.1.3 Cellular events required for successful angiogenesis  
Angiogenesis is a complex multistep process involving extensive interplay between 
cells, soluble factors, and extracellular matrix components (ECM) (Ribatti et al., 2012). 
In a quiescent state, endothelial cells form a monolayer of inactivated cells that lines the 
luminal surface of stable vessel tubes (Mazzone et al., 2009). In response to pro-
angiogenic factors, endothelial cells loosen their cell-cell junction contacts and pericytes 
and/or smooth muscle cells are removed from the existing vessel (Figure 1.3). During 
this process, proteases such as plasmin and matrix metalloproteinases (MMPs) are 
activated promoting degradation of the surrounding basement membrane, and allowing 
endothelial cells to invade the surrounding tissue and respond to environmental factors 
(Carmeliet and Jain, 2011; Adams and Alitalo, 2007). Only a small portion of endothelial 
cells (‘’tip cells’’) sense the angiogenic stimulus and will lead the newly sprouting blood 
10 
 
vessel (Figure 1.3). Endothelial tip cells (ETCs) continue sprouting further by filopodial 
extension, in a process guided by pro-angiogenic growth factors and involving 
semaphorins and ephrins (De Smet et al., 2009; Gerhardt et al., 2003). A variety of pro-
angiogenic inducers; such as VEGF, basic fibroblast growth factor (bFGF), 
angiopoietins, cytokines, chemokines, and others induce proliferation of endothelial 
cells (Ucuzian et al., 2010). ETCs are followed by endothelial ‘stalk cells’ (SCs) which 
support the elongation of sprouting vessels, generate the trunk of the new vessel, and 
connect the sprouting with the parental vessel (Iruela-Arispe et al., 2009; Kamei et al., 
2006). Upon contact with other vessel walls, ETCs lose their motile behaviour and fuse 
with the tip cell of another vessel by a process called anastomosis (Figure 1.3). The 
mechanisms underlying the process of anastomosis are not well understood, but it is 
believed that vessel fusion is influenced by a certain type of macrophages along with 
myeloid cells during the anastomotic process (Fantin et al., 2010). Even though nascent 
vasculature has been generated in this process they are still termed as ‘immature’ as 
they require maturation to acquire full functionality (Liekens et al., 2001). The final stage 
of angiogenesis requires recruitment of pericytes and smooth muscle cells to the newly 
formed vessel, which is induced by growth factors such as platelet derived growth 
factor-B (PDGF-B) and transforming growth factor-β1 (TGFβ-1). Additionally, deposition 
of the endothelial basement membrane and cell–cell junction stability suppress 
endothelial proliferation, migration and vascular permeability, and re-establishes a 
quiescent stage (Herbert and Stainier, 2011) (Figure 1.3). 
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Figure 1.3 Diagrammatic description of the steps involved in angiogenesis. (adapted from 
Carmeliet and Jain, 2011; Herbert and Stainier, 2011). ECM, extracellular matrix; TCs, tip cells; 
SCs, stalk cells.  
 
1.1.4 Molecular regulation of angiogenesis  
As we have mentioned earlier, regulation of angiogenesis is tightly controlled by multiple 
pro- and anti-angiogenic molecules. Most angiogenic inducers are proteins, mainly 
growth factors which stimulate endothelial cells to proliferate and migrate towards the 
stimuli. Up to 24 inducers of angiogenesis have been identified so far. The best studied 
of these pro-angiogenic factors are mentioned in table 1.1  
On the other hand, angiogenesis is down-regulated by a variety of inhibitors including 
angiostatin, endostatin, thrombospondin-1 (TSP-1) and others (Table 1.1). In this sense, 
Eriksson et al, showed that both angiostatin and endostatin inhibit endothelial cell 
migration in the presence of the angiogenic activators VEGF and FGF (Eriksson et al., 
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2003). Similarly, the anti-angiogenic effects of TSP-1 have been clearly defined in 
studies on angiogenesis in the tumour microenvironment (Good et al., 1990). 
 
Table 1.1 Regulators of angiogenesis  
 
 
Among all angiogenesis effectors, VEGF has emerged as a critical regulator of both 
pathological and physiological angiogenesis (Takahashi and Shibuya, 2005). Given the 
relevance of VEGF-dependent angiogenic stimulation in the work presented in this 
thesis, I will describe in detail the features and mechanism of action of this growth 
factor. 
1.1.5 The vascular endothelial growth factor protein family  
VEGF belongs to a protein family called the vascular endothelial growth factor (VEGF) 
family, that comprises seven members; VEGF-A, VEGF-B, VEGF-C VEGF-D, VEGF-E, 
svVEGF (snake venom VEGF) and PLGF (placental growth factor) (Takahashi and 
Shibuya, 2005). These proteins bind to three structurally different receptor tyrosine 
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kinases known as VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4) 
(Holmes et al., 2007). The molecular and biological function of each ligand and its 
receptors are thoroughly characterized. Each of these ligands has distinct tissue 
distribution, interaction with different receptor tyrosine kinases and diverse effects on 
the angiogenic process (Takahashi and Shibuya, 2005). I will focus on VEGF-A in this 
thesis, as it acts on endothelial cells and is implicated in both physiological and 
pathological angiogenesis. 
1.1.5a VEGF-A  
VEGF-A is the most potent stimulator of angiogenesis. It is produced by a wide variety 
of cells, organs and tissues including tumour cells, the corpus luteum, the heart, liver, 
stomach mucosa, adrenal cortex, cardiac myocytes, renal glomeruli, epithelial cells of 
the lung and macrophages (Berse et al., 1992). The importance of VEGF-A in vascular 
function was highlighted by the fact that inactivation of one or both alleles results in 
embryonic lethality at approximately 10.5 days, due to lack of vascular structure 
formation (Cameliet et al., 1996). Another study demonstrated that heterozygous knock-
out of VEGF-A results in embryonic lethality between days 11 and 12, with impairment 
of angiogenesis and blood-island formation (Ferrara et al., 1996).  
In humans, the VEGF-A gene is located on chromosome 6p21.3 (Vincenti et al., 1996). 
VEGF-A is composed of seven introns and eight exons (Figure 1.4).  
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Figure 1.4 Schematic diagram of major human VEGF-A mRNA splice variants (adapted 
from Holmes et al., 2007). VEGF-A comprises seven introns and eight exons that encode 
different structural isoforms. Alternative splicing of this RNA generates several different isoforms 
that vary in amino acid number; VEGF-A121, VEGF-A145, VEGF-A148, VEGF-A162, VEGF-
A165, VEGF-A183, VEGF-A189, VEGF-A206. In humans, VEGF-A165 is the most predominant 
form, and the major stimulator of angiogenesis. 
 
 
The VEGF-A protein exists in a number of different isoforms that result from alternative 
splicing of a single precursor RNA (Figure 1.4). In humans, nine VEGF-A splice variants 
have been detected: VEGF-A121, VEGF-A145, VEGF-A148, VEGF-A162, VEGF-A165, 
VEGF-A183, VEGF-A189, VEGF-A206 and also VEGF-A165b (Holmes et al., 2007). 
Although VEGF-A121, VEGF-A183 and VEGF-A189 are expressed in various tissues, 
VEGF-A165 is the most abundantly expressed isoform and has been identified as the 
main regulator of physiological and pathological angiogenesis (Robinson and Stringer, 
2001; Takahashi and Shibuya, 2005). Consistent with a role in pathological 
angiogenesis, VEGF-A165 is strongly expressed by tumoral cells, and its expression 
correlates with tumor progression (Ferrara N, 2004). Likewise, we have also mentioned 
in previous sections that elevated levels of VEGF have been detected in the vitreous 
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and aqueous fluids of patients with diabetic retinopathy (Aiello et al., 1994; Adamis et 
al., 1994). 
1.1.5b VEGF Receptors 
The biological effects of VEGF are mediated through binding to specific cell receptors 
(VEGFR) which are predominantly found in endothelial cells, although they are also 
expressed in other cell types. VEGFRs actively participate in the regulation of 
angiogenesis, vasculogenesis and lymphangiogenesis (Lohela et al., 2009). 
There are three VEGF receptors (VEGFR-1, -2, and -3) with different ligand-binding 
properties and tyrosine kinase activity (Takahashi and Shibuya, 2005; Ferrara et al., 
2003). Structurally, VEGFRs have an extracellular portion consisting of seven 
immunoglobulin-like domains, a single transmembrane spanning region and an inner 
cytoplasmic portion containing a split tyrosine-kinase domain (Figure 1.5) (Takahashi 
and Shibuya, 2005; Ferrara et al., 2003). 
VEGFRs function similarly to other tyrosine kinase receptors such as epidermal growth 
factor receptor (EGFR), hepatocyte growth factor receptor (HGFR), and platelet derived 
growth factor receptor (PDGFR) (Olsson et al., 2006). Ligand interaction with its 
corresponding receptor induces receptor dimerization that creates a docking site for 
signalling and, consequently, activation of the tyrosine kinase domain leading to 
receptor auto-phosphorylation (Stuttfeld and Ballmer-Hofer, 2009; Olsson et al., 2006). 
VEGFR-1 and VEGFR-2 are expressed in endothelial cells (Olsson et al., 2006). 
VEGFR-1 is also expressed in monocytes, macrophages and haematopoietic stem 
cells, playing an important role in the migration of these cellular types (Yao et al., 2011). 
VEGFR-3 is expressed in the lymphatic endothelium and plays a fundamental role in 
lymphangiogenesis (Olsson et al., 2006) (Figure 1.5) 
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Figure 1.5 VEGF receptor binding properties, expression and downstream functional 
effects (adapted from Holmes et al., 2007). 
 
1.1.5b(i) VEGFR-1 
VEGFR-1 is a 180-185 kDa glycoprotein that binds VEGF-A, VEGF-B and PIGF (Figure 
1.5) (Takahashi and Shibuya, 2005). The role of VEGFR-1 has been studied using 
knockout mouse models. Deletion of the VEGFR-1 gene in the mouse embryo is lethal 
at embryonic day E9.0 due to an increased number of vessels in the vasculature (Fong 
et al., 1995). Recent studies have shown that VEGFR-1 does not mediate VEGF-driven 
angiogenesis in endothelial cells. Instead, VEGFR-1 acts as a decoy receptor 
controlling the binding and signalling of VEGF to VEGFR-2 (Ferrara et al., 2003). 
1.1.5b(ii) VEGFR-2 
VEGFR-2, also known as kinase-insert domain receptor (KDR) and foetal liver kinase-1 
(Flk-1) is a 210-230 kDa glycoprotein that plays a critical role in endothelial survival, 
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proliferation, migration, and vascular development upon stimulation by VEGF-A (Figure 
1.5) (Terman et al., 1991; Takahashi and Shibuya, 2005). 
The VEGFR-2 gene is located on chromosome 4q11q12, in close proximity to the locus 
of another two receptors, PDGFR-α and C-KIT (Shibuya, 2002). Studies in VEGFR-2-/-  
mice have revealed that embryos deficient in VEGFR-2 die between days E8.5 and 
E9.5 due to lack of blood vessel organisation in the yolk sac and blood island formation, 
suggesting that VEGFR-2 is essential for the vascularisation of the embryo in early 
development (Shalaby et al., 1995). VEGF-A, -C, -D, and -E can bind to VEGFR-2 
triggering different physiological effects (Holmes et al., 2007). Binding of VEGF-A to 
VEGFR-2 activates numerous intracellular signalling pathways that trigger specific 
cellular processes involved in angiogenesis. Therefore the axis VEGF-A/VEGFR-2 has 
emerged as a critical regulator of both physiological and pathological blood vessel 
formation (Takahashi and Shibuya, 2005).  
1.1.6 Anti-angiogenesis therapies 
1.1.6a Inhibitors of the interaction VEGF-VEGF receptor 
1.1.6a(i) Bevacizumab (Avastin®) 
Bevacizumab has been the first anti-angiogenic drug used therapeutically (Shih and 
Lindley, 2006). It is a humanized anti-angiogenic monoclonal antibody and it was 
approved by the Food and Drug Administration (FDA) for treating metastatic and 
colorectal cancer in 2004. It has a long half-life of 17-21 days (Ferrara et al., 2004). It 
binds to VEGF with high specificity, thereby blocking the interaction between VEGF and 
its receptor and, subsequently, VEGF-mediated angiogenic signalling pathways (Shih 
and Lindley, 2006). This drug binds to all isoforms of VEGF. Bevacizumab has some 
possible side effects including impaired wound healing, proteinuria and severe 
hypertension (Shih and Lindley, 2006; Hurwitz et al, 2004). Kamba and McDonald, 2007 
reported that hypertension is thought to be the result of attenuation in nitric oxide 
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production by the endothelial nitric oxide synthase (eNOS) due to reduced eNOS 
activation as a consequence of VEGF blockage (Kamba and McDonald, 2007). The 
severe side effects associated with this therapy are due to long half-life of bevacizumab 
(Pieramici and Rabena, 2008). Bevacizumab has been approved in combination with 5-
fluorouracil-based chemotherapy for treatment of colorectal carcinoma. Use of 
bevacizumab in combination with 5-fluorouracil results in a reduction in blood volume, 
interstitial fluid pressure, and micro-vascular density in tumours (Willet et al, 2004).  
1.1.6(ii) Pegaptanib (Macugen®, EYE001, NX1838) 
Pegaptanib is an anti-angiogenic medicine for the treatment of neovascular wet age-
related macular degeneration (AMD). Pegaptanib, was approved in 2004 by the FDA for 
the treatment of wet AMD (Zhou and Wang., 2006). It is a single stranded nucleic acid 
aptamer containing 28 bases (Fraunfelder, 2006) that binds specifically and inhibits the 
activity of VEGF-A165 by blocking its interaction with VEGFR-2 (Pieramici and Rabena, 
2008). Administration of pegaptanib has been reported to significantly reduce vessel 
permeability, leakage, and neovascularisation in the retina of patients suffering from 
AMD (Gragoudas et al, 2004). The side effects associated to this drug are highly 
reduced and manageable (Zhou and Wang, 2006). In fact, most of adverse effects are 
related with the injection procedure rather than the drug itself (Gragoudas et al, 2004). 
Pegaptanib is also being considered for anti-angiogenic cancer treatment given the 
success obtained in the treatment of neovascular-related ocular disease.  
1.1.6a(iii) Ranibizumab (Lucentis®)  
Ranibizumab is a humanised monoclonal antibody fragment (Fab) from bevacizumab 
that was FDA approved in 2006. It binds to all isoforms of VEGF-A, inhibiting their 
activity by blocking the VEGF/VEGFR interaction and the initiation of intracellular 
signalling (Kourlas and Abrams, 2007). It has an approximately 20 times higher binding 
affinity for VEGF than bevacizumab (Pieramici and Rabena, 2008). Additionally, it can 
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penetrate better in tissues due to its small size compared to bevacizumab (Pieramici 
and Rabena, 2008). Ranibizumab treatment in patients with neovascular AMD reduced 
loss of visual acuity compared to sham-treated control patients. Few adverse effects 
were observed with the administration of this treatment, most severe being 
endophthamitis (Rosenfeld et al, 2006).   
1.1.6a(iv) VEGF-Trap 
VEGF-Trap is another inhibitor of VEGF that binds and inhibits the function of VEGF by 
preventing its interaction with VEGFR. It is generated using the second and third Ig 
domains of VEGFR-1 and VEGFR-2 respectively (which are the regions of the receptor 
involved in VEGF binding in each case). These regions are combined with a human IgG 
Fc fragment and the resulting molecule has the highest affinity for VEGF compared to 
other drugs (Chang et al, 2012; Holash et al, 2002). Additionally, VEGF-Trap is smaller 
in size than other inhibitors and therefore penetrates better in tissues (Pieramici and 
Rabena, 2008). It binds to all isoforms of VEGF-A, and additionally placental growth 
factor (PlGF-1 and -2) (Chang et al, 2012). Treatment of patients presenting 
neovascular AMD using VEGF-Trap resulted in a reduction in lesion size and choroidal 
neovascularisation and significantly improved visual acuity. Adverse effects are mainly 
conjunctival hemorrhage associated with the injection procedure. Few systemic side 
effects were observed such as bronchitis and infection of the upper respiratory and 
urinary tract (Heier et al, 2011).  
1.1.6b VEGFR Inhibitors 
VEGFR inhibitors are mainly monoclonal antibodies and receptor tyrosine kinase 
inhibitors (Casanovas et al, 2005). Monoclonal antibodies bind to the surface of VEGFR 
and impair binding of VEGF. Receptor tyrosine kinase inhibitors (such as small 
molecule inhibitors) bind directly to the ATP binding site in the cytosolic region of the 
receptor, and prevent both ATP binding and activation of signalling pathways (Gotink 
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and Verheul, 2010). Problems associated to treatments based on drugs inhibiting 
receptor tyrosine kinases are the low specificity given the huge number of receptors 
with tyrosine kinase activity in the cell. 
1.1.6b(i) Sunitinib (Sutent®, SU11248) 
Sunitinib, approved in 2006 by the FDA (Faivre et al, 2007), is a small molecule inhibitor 
that can bind directly to the ATP binding site of VEGFR, preventing both ATP binding 
and receptor activation (Gotink and Verheul, 2010). It inhibits cellular signalling by 
targeting multiple receptor tyrosine kinases. These include VEGFR-1, 2 and 3 and the 
platelet-derived growth factor receptor (PDGFR) (Faivre et al, 2007). Sunitinib treatment 
of patients and animal models with several kinds of tumour resulted in a significant 
reduction in tumour growth and microvessel density (Mendel et al, 2003; Motzer et al, 
2006). Side effects were observed such as diarrhoea, vomiting, fatigue, hypertension 
and hand-foot syndrome (delicate skin on the hands and feet that can blister and peel in 
severe cases) (Faivre et al, 2007). As sunitinib has a short-life it is suggested the 
recovery rate of adverse effects will be quicker (Kamba and McDonald, 2007). 
1.1.6b(ii) Sorafenib (Nexavar®, Bay 43-9006) 
Sorafenib was FDA approved in 2005 for the treatment of renal cell carcinoma (RCC) 
(Wilhelm et al, 2006). It is also a small molecule inhibitor that targets the intracellular 
region of VEGFR. This small molecule can pass through the membrane and bind to 
cytosolic regions of the receptor at a site next to the ATP binding site, preventing 
receptor interaction with ATP and signal transduction activation (Gotink and Verheul, 
2010; Wilhelm et al, 2006). Administration of sorafenib has been reported to reduce 
tumour growth and microvessel density in animal models and clinical trials of human 
patients (Wilhelm et al, 2004; Ratain et al, 2006). Unfortunately, this molecule is 
associated with some side effects including hypertension, fatigue, hand-foot syndrome 
and diarrhoea which could be reduced by dose reduction (Ratain et al, 2006).   
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1.1.6b(iii) IMC-1121b (Ramucirumab)  
IMC-1121b is a monoclonal antibody that targets VEGFR. It binds to VEGFR-2 and it 
works as a receptor antagonist, blocking the binding of all isoforms of VEGF to this 
receptor (Spratlin et al, 2010). Administration of ramucirumab in patients with advanced 
solid malignancies resulted in reduced perfusion and vascularity of tumours. The 
common side effects of ramucirumab include hypertension, proteinuria, abdominal pain, 
headaches, deep vein thrombosis (DVT) and vomiting (Spratlin et al, 2010).   
1.1.7 Pro-angiogenesis therapies  
Although interventional endovascular procedure and coronary artery bypass surgery are 
effective treatments to restore the blood flow to the ischaemic heart, some patients are 
unsuitable for surgical revascularization (Sachs et al., 2011). Therapeutic strategies to 
promote the formation of new blood vessels in the ischaemic organ (referred to as 
therapeutic angiogenesis) represent a promising alternative to treat these patients 
(Zachary and Morgan, 2011; Cooke and Losordo, 2015). The aim of therapeutic 
angiogenesis is to use angiogenic factors to induce the formation of a collateral blood 
supply, effectively bypassing an occluded diseased blood vessel in patients with 
coronary or peripheral artery disease, and thereby revascularising the ischaemic tissue 
(Deveza et al., 2012). To exploit the powerful angiogenic potential of VEGF, gene-, and 
protein-based therapeutic approaches aimed to deliver exogenous VEGF to ischaemic 
tissues have been developed in the last decades (Zachary and Morgan, 2011). A large 
body of data obtained from preclinical studies carried out in animal models of 
myocardial and limb ischaemic disease demonstrated that VEGF-based pro-angiogenic 
therapies result in successful reperfusion of the ischaemic organ (Ylä-Herttuala, 2013).  
Recent studies showed that intracoronary and intravenous administration of 
recombinant VEGF-A165 (rhVEGF) to patients with coronary artery disease improved 
myocardial perfusion and collateralisation (Hendry et al., 2001; Hendel et al., 2000). A 
22 
 
subsequent phase II trial “VEGF in Ischaemia for Vascular Angiogenesis (VIVA)” has 
indicated that intravenous delivery of VEGF is safe but does not translate into a 
significant improvement of patients after 60 days of treatment, only a high dose of 
VEGF resulted in significant improvement at 120 days in angina patients.  
The Isner group first established an alternative way (gene therapy) of delivering 
therapeutic VEGF to achieve a more sustained therapeutic effect. The authors reported 
that delivery of a cDNA plasmid encoding VEGF-A165 (phVEGF165) improved 
myocardial perfusion after 3 months (Symes et al.,1999; Vale et al., 2000; Losordo et 
al., 1999). Unfortunately, disappointing results were obtained later with other phase II 
trials (Rissanen and Ylä-Herttuala, 2007). Intramuscular injection of phVEGF-165 to 
patients with peripheral artery disease and critical limb ischaemia also produced 
negative results (Kusumanto et al., 2006). 
Adenovirus-mediated delivery of different VEGF isoforms (VEGF121 and VEGF165) 
has also been assayed as a treatment for cardiovascular ischaemic disease. A large 
body of phase I trials showed that this method of VEGF delivery is safe and significantly 
improved clinical benefits, either when given alone or as an adjutant to coronary artery 
bypass grafting (Rosengart et al., 1999). However, in phase II trials, administration of 
adenovirus encoding VEGF-121 by percutaneous injection has failed to provide 
evidence of clinical benefits (Zachary and Morgan, 2011). Similarly, delivery of Ad-
VEGF121 to patients suffering from peripheral artery disease did not promote any 
improvement (Rajagopalan et al., 2003).  
It is clear that trials of therapeutic angiogenesis on human cardiovascular ischaemic 
diseases have only shown limited benefits for patients thus far (Gupta et al., 2009). The 
reasons behind lack of clinical success for therapeutic angiogenesis are complex, but 
failure to restore efficient VEGF activity in the ischaemic organ remains a major problem 
in current approaches (Ylä-Herttuala, 2013; Gupta et al., 2009; Zachary and Morgan, 
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2011). There is an urgent need to identify key regulators of pro-angiogenic signal 
transduction pathways activated by VEGF, to design more efficient interventions that 
enhance VEGF-driven angiogenesis in ischaemic organs. In this sense, the detail 
characterisation of the intracellular signalling pathways activated by VEGF binding to 
VEGFR-2 in endothelial cells is receiving a lot of attention. 
1.1.8 VEGFR-2 signalling pathways in angiogenesis 
Signalling pathways activated by binding of VEGF-A to VEGFR-2 include the 
Extracellular Signal-Regulated Kinase (Erk) pathway, the p38 Mitogen-Activated Protein 
Kinase (MAPK) pathway, activation of phospholipase C, the phosphatidylinositol 3-
kinase/Akt pathway and the calcineurin/Nuclear Factor of Activated T-cells (NFAT) 
pathway. 
1.1.8a Extracellular signal-regulated kinase (Erk) pathway 
The Erk signalling cascade is considered a central MAPK pathway that plays an 
important role in the regulation of endothelial cell proliferation, differentiation, and cell 
cycle (Yoon and Seger, 2006). The Erk pathway is activated by sequential 
phosphorylation of protein kinases in different points of the cascade (Shaul and Seger, 
2007). Binding of VEGF to VEGFR-2 triggers activation of the signalling protein Ras. 
Activated Ras phosphorylates the MAP kinase kinase kinase (MAPKKK) Raf that 
becomes activated by this phosphorylation. Activated Raf phosphorylates the MAP 
kinase kinase (MAPKK) MEK1/2 which consequently phosphorylates the MAP kinase 
(MAPK) Erk1/2. Specific inhibitors that block the phosphorylation of Erk1/2 significantly 
attenuate VEGF-induced endothelial cell migration and proliferation, confirming the 
involvement of this pathway in these angiogenic processes (Meloche and Pouyssegur, 
2007; Dellinger and Brekken, 2011). 
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1.1.8b P38 Mitogen Activated Protein Kinase 
The p38 MAPK family consists of four isoforms; p38-α, -β, -γ, and -δ. This protein 
becomes phosphorylated (and therefore activated) by an upstream MAPKK called 
MEK3/6. Pharmacologic inhibition of p38 attenuates VEGF-stimulated cell migration 
(McMullen et al., 2005; Rousseau et al., 1997). 
1.1.8c Phosphatidylinositol-3 Kinase (PI3K)  
Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that play an important role in 
various cellular functions including cell proliferation, adhesion, migration, survival and 
angiogenesis (Sasore and Kennedy, 2014 and Karar and Maity, 2011). The PI3K is 
mainly activated by tyrosine kinase receptor and G-protein-coupled receptors. Given the 
huge variety of physiological roles of the PI3K we will focus on this section on 
describing its role in angiogenesis as this is the main subject of this thesis. Several 
works have demonstrated that VEGF induced activation of PI3K signalling in endothelial 
cells is essential for the progression of angiogenesis (Tsuji-Tamura and Ogawa, 2016). 
The PI3K signalling pathway plays an important role in the formation of normal blood 
vessel during embryonic development (Hamada, 2005). Activation of PI3K/Akt signalling 
translates into increased expression of VEGF in tumor cells further activating 
endothelial angiogenic signalling (Cheng et al., 2017). Furthermore, PI3K/Akt modulates 
the expression of other angiogenic factors including Nitric Oxide (NO) and angiopoietin. 
Hence, the PI3K pathway is important in both physiological and pathological blood 
vessel formation.  
The PI3K family is composed of three classes of PI3K; class I, class II, class III. This 
classification is mainly based on their domain structures and lipid surface preferences. 
Class I PI3K composed of 4 catalytic isoforms; p110α (PIK3CA), p110β (PIK3CB), 
p110γ (PIK3CB), and p110δ (PIk3CD) (Karar and Maity, 2011and Graupera and 
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Potente, 2013). Although these four isoforms are expressed in endothelial cells, only 
p110α is required for vessel sprouting (Soler et al., 2015). Deletion of kinase p110α 
catalytic subunit of PI3K in mice lead to vascular defect during the development stage 
(Karar and Maity, 2011). The involvement of class II and class III PI3K in angiogenesis 
is not understood at present.   
1.1.8d Protein Kinase C (PKC) 
PKC contains at least 10 isoenzymes grouped into three classes; conventional PKC 
(cPKC), novel PKC (nPKC), and atypical PKC (aPKC). PKC signalling enhances 
angiogenic activity in endothelial cells induced by VEGF stimulation (Xu et al., 2008; 
Harhaj et al., 2006).  
1.1.8e Calcineurin/NFAT pathway 
Several works have demonstrated that VEGF-induced activation of the 
calcineurin/NFAT pathway in endothelial cells is an essential step in the progression of 
VEGF-driven angiogenesis (Armesilla et al., 1999; Hernandez et al., 2001; Schabbauer 
et al., 2007; Ryeom et al., 2008). 
Given the relevance of VEGF-induced activation of the calcineurin/NFAT pathway for 
the topic of this thesis, I will describe in detail the molecular features of this pathway in 
the following sections.  
1.2 The calcineurin/NFAT pathway 
1.2.1 Calcineurin 
Calcineurin is a calcium and calmodulin-dependent serine/threonine phosphatase of 
approximately 80 kDa. It is also known as protein phosphatase 2B (PP-2B) (Rusnak 
and Mertz, 2000). Originally identified in the brain, calcineurin was later shown to have a 
role in diverse biological processes such as regulation of the immune response (Snyder 
et al., 1998), apoptosis (Klee et al., 1998) and angiogenesis (Hernandez et al., 2001). 
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Additionally, it plays an important role in cardiac hypertrophy (Molkentin, 2004) and 
central nervous system functions (CNS) (Winder and Sweatt, 2001). 
Calcineurin is a heterodimeric protein composed of two subunits; calcineurin A (a 
catalytic subunit) and calcineurin B (a regulatory calcium-binding subunit) of 
approximately 60 kDa and 20 kDa respectively (Li et al., 2010; Rusnak and Mertz, 
2000). The A subunit is composed of four different regions; the N-terminal region, the 
catalytic domain, the regulatory domain and the C-terminal region. The regulatory 
domain is further subdivided into the calcineurin B binding region, the calmodulin 
binding region and an auto-inhibitory peptide region (Figure 1.6) (Li et al., 2010).  
There are three calcineurin A isoforms (alpha, beta and gamma), encoded by three 
different genes. The polypeptides produced by these genes have different N- and C-
terminal tails but highly conserved amino acid sequences in the catalytic and regulatory 
domains (Molkentin, 2004). The isoforms alpha and beta are distributed throughout the 
body, while γ is more restricted to the brain and testis (Gooch et al., 2004). 
Calcineurin B is highly conserved, encoded by two genes which generate two different 
isoforms; Cn B1 which is expressed ubiquitously, and Cn B2 that is more localised in 
testis (Shou et al., 2015). 
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Figure 1.6 General structure of calcineurin (adapted from Shou et al., 2015). The calcineurin 
heterodimer is formed by two subunits:  calcineurin A (catalytic subunit) and calcineurin B 
(regulatory calcium-binding subunit). The A subunit is composed of four different regions; the N-
terminal region, the catalytic domain, the regulatory domain and the C-terminal region. The 
regulatory domain is further subdivided into the calcineurin B binding region (CnB), the 
calmodulin binding region (CnM) and an auto-inhibitory peptide region (AID). Calcineurin B has 
a main region with four Ca2+- binding EF-hand motifs. 
 
Increments in the level of intracellular calcium promote the formation of calcium-
calmodulin complexes that bind to the regulatory subunit of the heterodimer, activating 
calcineurin phosphatase activity (Schulz and Yutzey, 2004). The best known substrate 
of activated calcineurin is the family of NFAT (Nuclear Factor of Activated T-cells) 
transcription factors (Li et al., 2010). 
 
1.2.2 The NFAT protein family 
The NFAT family of transcription factors consists of five members; NFAT1 (NFATc2/ 
NFATp), NFAT2 (NFATc1/NFATc), NFAT3 (NFATc4), NFAT4 (NFATc3/ NFATx) and 
NFAT5 (tonicity enhancer binding protein) (Mancini and Toker, 2009). 
The NFAT proteins were first discovered in activated T lymphocytes, but later studies 
have shown that this family of proteins is ubiquitously expressed and plays an important 
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role in many pathophysiological processes such as cardiac development, tumour 
progression, cardiac hypertrophy, diabetes, vascular and neural development, etc 
(Crabtree and Olson, 2002). 
Structurally, NFATs contain a region of high homology among all its members (NFAT 
homology region, NHR), a region which shows homology to the Rel protein (Rel 
homology region, RHR), and a C-terminal domain (Figure 1.7) (Shaul et al., 2007).  
 
Figure 1.7 General structure of NFAT (adapted from Shou et al., 2015) NFAT proteins show a 
Rel-homology region (RHR), an NFAT homology region (NHR) and a C-terminal domain. The 
NHR contains an N-terminal transactivation domain (TAD), calcineurin binding sites, nuclear 
localisation sequence (NLS) and nuclear export signal (NES). It also contains several serine-
rich motifs including SRR1, SRR2, SP1, SP2 and SP3. The RHR includes the DNA binding 
domain and sites for interaction with transcriptional binding partners such as Fos and Jun. 
 
The NHR region is subdivided into an amino terminal transactivation domain (TAD) 
essential for the activity of the protein, calcineurin-binding sites and a nuclear 
localisation signal (NES) (Mancini and Toker, 2009; Li et al., 2010). In the NHR region, 
we also find several intermediate serine-rich motifs called SRR1, SRR2, SP1, SP2, and 
SP3 (Hogan et al., 2003). The RHR region contains the DNA binding domain and also 
recognition points for other transcription factors such as Fos and Jun that bind NFATs in 
certain circumstances (Shaul et al., 2007) (Figure 1.7). NFATs1-4 are synthesized as 
constitutively phosphorylated proteins that are expressed in the cytoplasm of the cell. In 
response to increments in the intracellular calcium concentration, calcineurin becomes 
activated. Upon activation, calcineurin dephosphorylates NFAT1-4 transcription factors 
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promoting their translocation from the cytoplasm to the nucleus. Once in the nucleus 
NFAT1-4 bind to specific DNA motifs located in the promoter regulatory regions of 
target genes, switching on the transcription of these genes (Zaichuk et al., 2004; Ryeom 
et al., 2008; Armesilla et al., 1999). Nuclear NFAT1-4 are deactivated by 
rephosphorylation by specific kinases. Rephosphorylation of the protein induces a 
conformational change that results in exposure of a nuclear export sequence, triggering 
the movement of NFAT back to the cytoplasm (Beals et al., 1997; Llang et al., 2003).  
1.2.3 Members of NFAT 
1.2.3a NFAT1 
Several studies are shown that NFAT1 is involved in the regulation of the immune 
response. NFAT1-/- mice have splenomegaly and hyperproliferation of both B and T 
cells (Hodge et al., 1996). Horsley et al., 2001 demonstrated that NFAT1 plays a role in 
the regulation and growth of skeletal muscle (Horsley et al., 2001). 
1.2.3b NFAT2 
NFAT2 has been shown to play an important role in cardiac development, specifically in 
valve formation. In a study by De la Pompa et al., 1998 the authors showed that NFAT2-
/- mice are embryonic lethal at day E14.5 due to lack of development of the cardiac 
valves and septa (De la Pompa et al., 1998). Another study using NFAT2-/- mice also 
revealed a pathological phenotype of congestive heart failure between days E13.5 to 
E17.5 due to loss of aortic and pulmonary valve formation (Ranger et al., 1998a). 
1.2.3c NFAT3 
Deletion of NFAT3 in NFAT3-/- mice had no effect on embryonic development. However, 
when combined with NFAT4-/-, the double knock out (DKO) NFAT3-/-; NFAT4-/- shows 
embryonic development defects starting around day E10.5. These isoforms of NFAT are 
also required for recruitment of smooth muscle cells to the vessels to enhance stability 
(Graef et al., 2001).  
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1.2.3d NFAT4 
Using NFAT knockout mice, NFAT4 has been shown to play an important role in the 
stabilisation of the vasculature and functionality of the developing heart. It has also been 
shown that NFAT4 is implicated in the regulation of skeletal muscle growth at E17.5 
(Graef et al., 2001). Double knockout of NFAT1 and 4 showed that these proteins have 
a role in the negative regulation of the immune response. NFAT1/4 DKO mice show an 
increase in mast cells and eosinophils in the spleen and lymph nodes (Ranger et al., 
1998a). 
1.2.3e NFAT5 
NFAT5 is included in the NFAT family of transcription factors because it has similar 
structural features. However, it differs from other NFATs in its mechanisms of activation. 
In contrast to members NFAT1-4 that are synthesised as phosphorylated proteins 
located in the cytoplasm of the cells and activated by calcineurin-dependent 
dephosphorylation and subsequent nuclear translocation, NFAT5 activation is 
independent of calcineurin, and a high proportion of NFAT5 is constitutively localised in 
the nucleus, although cellular activation is required for total NFAT nuclear localisation 
(Aramburu et al., 2006). 
Functionally, NFAT5 activates a cellular gene expression programme in response to 
osmotic stress (Aramburu et al., 2006; Lopez-Rodriguez et al, 2001; Drews-Elger et al., 
2009). Additionally, Buxade et al., 2012 have recently reported that NFAT5-deficient 
mice show a remarkable susceptibility to Leishmania major infections (Buxade et al., 
2012) revealing NFAT5 as a crucial inducer of the expression of genes essential for 
antimicrobial immunity. 
Although the role of NFAT1-4 members in endothelial cell biology and, in particular, 
endothelial cell angiogenesis has been extensively studied (Armesilla et al., 1999; 
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Hernandez et al., 2001; Urso et al. 2011) whether NFAT5 regulates the expression of 
endothelial genes during angiogenesis has not been explored so far.  
1.2.4 Inhibitors of the calcineurin/NFAT pathway 
1.2.4a Cyclosporin A and FK506 
Cyclosporin A (CsA) and tacrolimus (FK506) are two effective immunosuppressive 
drugs widely used in organ transplantation and dermatology. Application of these 
compounds in basic research has contributed to study the molecular mechanisms that 
regulate calcineurin-dependent signalling pathways (Sieber and Baumgrass, 2009). 
These two immunosuppressive drugs bind to small intracellular proteins; cyclophilin A 
and FK506 binding protein (FKBP12) respectively (Li et al, 2011; Martínez-Martínez and 
Redondo, 2004). These inhibitory complexes interact with active sites of calcineurin 
preventing its interaction with NFAT (Ruff and Leach, 1995; Loh et al., 1996). Clinical 
use of CsA and FK506 is associated with severe side effects in the patient, including 
kidney damage, renal failure, hypertension and gastrointestinal problems, therefore 
restricting their use in treating chronic diseases (Martínez-Martínez and Redondo, 
2004). 
1.2.4b Calcineurin Homologous Protein (CHP) 
Lin et al., 1999 proved that calcineurin is also the target of a novel Ca2+-binding protein 
called calcineurin homologous protein (CHP) which is ubiquitously expressed. CHP 
shares a high percentage of sequence homology with CnB and with CaM (65% and 
59% respectively). The authors demonstrated that overexpression of CHP in Jurkat and 
HeLa cells blocks nuclear translocation of NFAT in response to PMA and ionophore 
stimulation. Furthermore, overexpression of CHP inhibits calcineurin phosphatase 
activity by preventing the assembly of calcineurin with CnB and CaM. This data strongly 
demonstrated that CHP attenuates the activity of the calcineurin/NFAT signalling 
pathway (Lin et al., 1999). 
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1.2.4c A-Kinase-Anchoring Protein (AKAP79) 
AKAP79 is an approximately 79 kDa protein kinase A anchoring protein, that interacts 
with calcineurin and inhibits its activity (Martínez-Martínez and Redondo, 2004). It is 
mainly expressed in T-cells and neurons (Kashishian et al, 1998). Kashishian et al, 
1998 reported that overexpression of AKAP79 inhibits NFAT activation induced by PMA 
and ionophore stimulation (Kashishian et al, 1998). Additionally, co-expression of 
calcineurin and AKAP79 showed translocation of calcineurin from the cytoplasm to the 
membrane confirming the interaction between the two proteins (Dell’Acqua et al, 2002).    
1.2.4d Cabin 1/Cain  
Cabin1 (calcineurin binding)/ cain (calcineurin inhibitor) is an ubiquitously expressed 
230 kDa phosphoprotein that interacts with calcineurin and inhibits its activity (Lai et al, 
1998; Sun et al, 1998). Binding of Cabin 1 to calcineurin is dependent on both calcium 
signalling and PKC activation. As with AKAP79 and CHP, overexpression of Cabin 1 in 
T-cells downregulates calcineurin phosphatase activity and consequently attenuates 
NFAT activation (Sun et al, 1998). 
1.2.4e Regulator of calcineurin 1 (RCAN1) 
The human RCAN1 gene, also referred to Down syndrome candidate region 1 
(DSCR1), myocyte-enriched calcineurin interacting protein 1 (MCIP1), Adapt 78, and 
calcipressin, is located on chromosome 21, near the portion of the Down Syndrome 
Critical Region (Fuentes et al., 1997; Davies et al, 2007). This gene is comprised of 7 
exons. Exons 1-4 are alternatively spliced, resulting in two main isoforms RCAN1-1 and 
RCAN1-4. Exon 1 gives rise to the isoform RCAN1.1 (Genescà et al., 2003). Exon 2 
does not have a methionine start site important for translation, and exon 3 encodes for 
only three amino acids (Yang et al., 2000). Exon 4 gives rise to isoform RCAN1.4 which 
contains 15 binding sites for NFATs in the regulatory region that controls expression of 
isoform 1.4 (Holmes et al., 2010; Genescà et al., 2003).  
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Several studies have shown VEGF-stimulated induction of RCAN1.4 in a variety of 
endothelial cells. Only RCAN1.4 is upregulated in response to VEGF, while RCAN1.1 is 
unaffected (Iizuka et al., 2004; Yao and Duh, 2004). VEGF-mediated upregulation of 
RCAN 1.4 is blocked by inhibitors of calcineurin A such as CsA, FK506, or an anti-
VEGFR-2 monoclonal antibody (Chan et al., 2005). Maximal induction of RCAN1.4 
expression in human dermal microvascular endothelial cells has been shown to require 
activation of the calcineurin/NFAT pathway and the PKC-delta pathway (Holmes et al., 
2010).  
Overexpression of RCAN1 protein inhibits calcineurin in the nanomolar range, acting in 
a similar way to the pharmacological agents FK506 and cyclosporin A (Chan et al., 
2005). 
Over-expression of RCAN1.4 in an animal human tumour xenograft model showed 
reduced vascular density and melanoma growth, highlighting that induction of RCAN1.4 
results in a negative feed-back mechanism that subsequently inhibits the 
calcineurin/NFAT pathway (Minami et al., 2004).  
Analysis of endothelial cell function in cells undergoing siRNA-mediated silencing of 
RCAN1 showed that lack of RCAN1 resulted in disrupted VEGF-mediated tubular 
morphogenesis and cell migration (Holmes et al., 2010). Endothelial cells isolated from 
RCAN1-/- mice show increased apoptosis (Ryeom et al., 2008) suggesting that 
RCAN1.4 functions to negatively regulate calcineurin-dependent apoptosis in 
endothelial cells and this role of RCAN1 is essential for successful angiogenesis. 
1.2.4f Plasma membrane calcium ATPase (PMCA) 
Plasma membrane calcium ATPases (PMCAs) have been recently characterised as 
novel regulators of signal transduction pathways (including the calcineurin/NFAT 
signalling pathway) via interaction with its partner proteins. Several studies have 
demonstrated a role for PMCA as an inhibitor of the calcineurin/NFAT pathway in breast 
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cancer cells (Holton et al., 2007), cardiomyocytes (Wu et al., 2009) and VEGF-
stimulated endothelial cells (Baggott et al., 2014). Ectopic expression of PMCA4 in 
HEK293 cells was shown to downregulate NFAT activation triggered by stimulation of 
the cells with PMA and calcium ionophore (Buch et al., 2005). A similar result was 
observed in cells overexpressing recombinant PMCA2 (Holton et al., 2007). We have 
also reported that PMCA4 is an endogenous inhibitor of calcineurin-dependent 
angiogenesis (Baggott et al., 2014) and for that reason we have selected PMCA4 for 
the experiments conducted in this thesis. Because of the relevance of PMCA proteins in 
the work carried out in this thesis, I will describe in the following sections the main 
features of the PMCA family of proteins formed by four members (PMCA1-4). 
1.3 Plasma membrane calcium ATPase pump (PMCA)  
PMCAs belong to the large super family of P-type ATPase calcium transporter 
membrane proteins which also includes, Sarcoplasmic Endoplasmic Reticulum Calcium 
ATPase (SERCA), the sodium-potassium ATPase (Na2+/K+-ATPase), hydrogen-
potassium ATPase (H+/K+-ATPase) and others (Verma et al., 1988). PMCAs transport 
calcium from the cytoplasm to the extracellular environment using the energy released 
by hydrolysis of adenosine triphosphate (ATP) into adenosine diphosphate (ADP) 
(Palmgren and Nissen, 2011). PMCAs extrude calcium with low capacity but high 
calcium affinity (Carafoli et al., 2000). 
1.3.1 Calcium transport by PMCAs 
PMCAs can be found in two conformational states known as E1 and E2 (Figure 1.8) 
(Carafoli E, 1991). In the E1 state, the conformation of PMCAs expose a high affinity 
calcium binding site to the cellular cytosol allowing incorporation of calcium into the 
pump. Binding of calcium leads to phosphorylation of the protein in an aspartic residue 
(conserved in all PMCA isoforms) in a process that requires hydrolysis of ATP. This 
phosphorylated intermediate is known as E1-P (Figure 1.8). The conformation of PMCA 
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at E1-P is not stable, and thus, in a mechanism promoted by Mg2+, the pump undergoes 
a conformational change that results in a more stable intermediate called E2-P. The 
conformational change that mediates the E1-P to E2-P transition places the calcium 
binding site on the external side of the plasma membrane, effecting calcium 
translocation and its release into the extracellular medium (Figure 1.8). E2-P is then 
converted into a dephosphorylated intermediate E2 that will finally revert to the original 
state E1, in a transition accelerated by Mg2+, completing the cycle (Figure 1.8) (Adamo 
et al., 1990). 
 
 
 
Figure 1.8 Model depicting the molecular events implicated in PMCA-mediated calcium 
transport through the plasma membrane (adapted from Adamo et al., 1990). E1, PMCA at 
conformational state 1. E1-P, phosphorylated intermediate of PMCA in the conformational state 
E1. E2-P, phosphorylated intermediate of PMCA in the conformational state E2. E2, PMCA at 
conformational state E2.  
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1.3.2 Structure of PMCAs 
The PMCA protein is formed by a single polypeptide chain. The putative structure of 
PMCAs consists of ten transmembrane (TM) segments linked by five extracellular short 
loops with the majority of the protein being cytosolic (Figure 1.9) (Kindmark et al., 1994). 
The cytosolic part of PMCAs is further subdivided into four main domains and two small 
loops (Figure 1.9).  
 
 
Figure 1.9 The membrane topology of PMCAs (adapted from Di Leva et al 2008; Strehler and 
Zacharias, 2001) PMCAs consist of ten transmembrane domains with five extracellular and six 
intracellular domains (N-terminal, intracellular domain between TM2 and TM3 (Transduction 
domain), intracellular domain between TM4 and TM5, two small intracellular loops and C-
terminal region that contains a binding site for calmodulin (CaMBD).  
 
The first cytoplasmic domain is the N-terminal region which contains 80-90 amino acids. 
The second domain corresponds to an intracellular loop located between TM2 and TM3 
which is also called the transduction domain. The third one is a large intracellular loop 
37 
 
located between TM4 and TM5 which corresponds to the catalytic domain of the protein 
(Figure 1.9). This domain contains the aspartic residue phosphorylated in the E1-P 
intermediate state of the calcium translocation cycle and the binding site for ATP. The 
catalytic domain is followed by two small intracellular loops connecting TM6 with TM7 
and TM8 with TM9. The C-terminal domain harbours a binding site for calmodulin 
(CaMBD) (regulatory site) which is involved in the regulation of PMCA activity 
(Figure1.9) (Di Leva et al., 2008). 
1.3.3 PMCA isoforms and tissue distribution 
As previously mentioned, there are four isoforms of PMCA (PMCA1-4) encoded by four 
distinct genes (Di Leva et al., 2008). RNA alternative splicing in two possible splicing 
sites (site A located in the first intracellular loop, and site C located in the COOH-
terminal tail) generates more than 20 PMCA splice variants (Strehler and Zacharias, 
2001). Differences in the amino acid sequences between these four isoforms are found 
mostly in the N-terminal and C-terminal domains of the protein (Strehler and Zacharias, 
2001).  
1.3.3a PMCA1 
PMCA1 is widely distributed in all tissues but most highly expressed in brain, lungs and 
intestine (Di Leva et al., 2008). PMCA1 is believed to have a major ‘’housekeeping’’ or 
developmental function as PMCA1-/- mice do not survive past embryonic development 
(Okunade et al., 2004). PMCA1 has recently been reported to have a critical role in the 
regulation of blood pressure as heterozygous PMCA1+/- mice present elevated blood 
pressure (Fujiwara et al., 2014). Consistently with this data, mice with tissue-specific 
deletion of PMCA1 in vascular smooth muscle cells exhibit elevated systolic blood 
pressure. Furthermore, femoral arteries from these mice present enhanced contractility 
to phenylephrine (Kobayashi et al., 2012). Importantly, single nucleotide polymorphisms 
in the PMCA1 gene have a strong association with hypertension in different human 
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ethnic groups (Tabara et al., 2010; Ganesh et al., 2013, Wang et al., 2012; Xi et al., 
2012). All these data strongly suggests a pivotal role for PMCA1 in blood pressure 
regulation, although the molecular mechanisms underlying this function of PMCA1 are 
still largely unknown. 
1.3.3b PMCA2 
PMCA2 has a more restricted tissue distribution and is localised to the brain, liver, 
uterus, kidney, cochlear hair cells and lactating mammary glands. PMCA2 plays an 
essential role in neuronal calcium homeostasis (Kurnellas et al., 2006). It also has a 
critical role in the physiology of both the vestibular and auditory systems as PMCA2-/- 
mice are profoundly deaf and show difficulties in maintaining balance (Kozel et al., 
1998). During lactation there is a significant up-regulation in the expression of PMCA2 
in mammary glands (Reinhardt et al., 2004). This up-regulation is connected with an 
increase of calcium levels in milk, suggesting that PMCA2 is involved in calcium 
transport from blood to milk during lactation. Supporting this idea, milk from PMCA2-null 
mice contains 60% less calcium than milk produced by heterozygous or wild-type mice 
(Reinhardt et al., 2004). PMCA2 not only plays an important role in mammary gland 
physiology but also in breast cancer progression. PMCA2 expression is clearly 
upregulated in breast cancer cell lines (Lee et al., 2005). Several lines of evidence have 
reported that PMCA2 protects breast cancer cells from apoptosis and, in this way, it 
contributes to the progression of breast cancer (VanHouten et al., 2010; Peters et al., 
2016)  
1.3.3c PMCA3  
PMCA3 is predominantly present in choroid plexus and in skeletal muscle (Strehler and 
Zacharias, 2001). However, its physiological function is still unclear as PMCA3 knockout 
models have not been determined to date (Prasad et al., 2004). 
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1.3.3d PMCA4 
PMCA4 is ubiquitously expressed. Analysis of mice deficient in PMCA4 are starting to 
unravel the function of this isoform in specific tissues and cell types. For example, 
PMCA4-/- mice have been reported to be infertile due to defects in sperm motility (Schuh 
et al., 2004). Several studies using PMCA4-deffficent mice have also shown that 
PMCA4 plays an important role in the pathophysiology of the heart. PMCA4 has been 
implicated in the regulation of the inotropic response of cardiomyocytes to β-adrenergic 
stimuli (Oceandy et al., 2007; Mohamed et al., 2009). Deregulation of PMCA4 function 
has been linked as well to cardiac pathology. Several groups have investigated the role 
of PMCA4 in the progression of cardiac hypertrophy using mice deficient in PMCA4, but 
the outcomes of their studies have revealed contradictory results. Whereas Wu et al., 
2009 reported that PMCA4 antagonizes cardiac hypertrophy induced by transverse 
aortic constriction (Wu et al., 2009), Mohamed et al., 2016 have recently shown that 
deletion of PMCA4 (systemically or specifically in fibroblasts) attenuates the 
hypertrophic response in the heart induced by this stimulus. In this work, the authors 
also demonstrate that specific ablation of PMCA4 in cardiomyocytes does not produce 
this effect. Animal models of cardiomyopathy-induced cardiac hypertrophy have also 
shown that loss of PMCA4 blocks the development of cardiac hypertrophy (Prasad et 
al., 2014). Using gain-of-function mouse models Ocenday et al., reported that 
overexpression of PMCA4 in cardiomyocytes increases cardiac hypertrophy induced by 
chronic stimulation with isoproterenol (Ocenday et al., 2007). The reason for 
discrepancies in these data with the initial observation reported by Wu et al is not 
understood at present.   
PMCA4 has also been implicated in the regulation of VEGF induced angiogenesis in 
vivo and in vitro (Baggott et al., 2014). PMCA4-/- mice present enhanced post-ischemic 
hindlimb perfusion 5 and 14 days after surgery compared to wild type littermates 
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(Baggott et al., 2014). It is this data that prompted me to formulate the hypothesis tested 
in this thesis and that will be explained later in detail. 
1.3.4 Activation of PMCA activity  
PMCA has poor affinity for calcium in an unstimulated state and needs to be activated 
to increase its affinity for calcium (Cheung et al., 1980). A number of mechanisms 
including modification by kinases, interaction with proteins, cleavage, and self-
association increase the affinity of PMCA for calcium (Di Leva et al., 2008). The 
traditional endogenous activator of the pump is calmodulin, which also acts as a 
regulator of other calcium-dependent enzymes (James et al., 1988; Vorherr et al., 
1990). PMCAs contain a calmodulin binding domain (CaMBD) located in the C-terminus 
of the protein (Figure 1.10). This domain interacts with the first intracellular loop (located 
between TM2 and TM3) and with the large catalytic domain of the pump, acting as an 
auto-inhibitory domain that maintains the protein in an inactive state. This conformation 
of the protein is known as the ‘’closed’’ conformation (Figure 1.10). Increments in the 
level of intracellular calcium prompt the association of calcium-calmodulin complexes to 
the CaMBD, displacing the interactions with other regions of the PMCA and activating 
the pump (Figure 1.10) (James et al., 1988; Vorherr et al., 1990). This confirmation of 
the protein is called the ‘’open’’ conformation. PMCAs fluctuate between the ‘’open’’ and 
‘’closed’’ (active-inactive) conformations depending on the concentration of intracellular 
calcium. Enyedi et al., 1989, proved that the CaMBD acts as an auto-inhibitory 
mechanism by using a mutant of PMCA4 that lacks the last 120 residues (including the 
28-aminoacids of the calmodulin binding inhibitory domain). They showed that this 
mutant was constitutively active, independently of calcium and calmodulin, and was 10 
times more active than the wild-type protein (Enyedi et al., 1989).  
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Figure 1.10 Activation of PMCAs (adapted from Di Leva et al 2008). A) In an inhibited state 
the calmodulin binding domain of the pump interacts with the intracellular domains. B) In an 
activated state, calmodulin binds to the calmodulin binding site releasing the interaction of the 
auto-inhibitory domain, which consequently activates the pump.  
 
The activity of PMCAs is also regulated by acid phospholipids. Specifically, 
phosphatidylinositol 4,5 bisphosphate has been shown to activate PMCAs in human 
erythrocytes by interacting with two binding domains; one is located to the intracellular 
loop between TM2 and TM3, and the second in the C-terminal at the CaMBD site (Niggli 
et al., 1981; Brodin et al., 1992). The mechanism by which acidic phospholipids activate 
PMCAs has not been thoroughly studied yet.  
Under certain conditions, PMCAs are phosphorylated by a variety of kinases including 
protein kinase A (PKA), protein kinase C (PKC), and cAMP-dependent protein kinase 
and GMP-dependent protein kinase (Monteith, et al., 1999). PKA directly 
phosphorylates PMCAs at a serine residue which is located downstream of the CaMBD. 
PKC also activates the pump by phosphorylating a threonine residue which is located in 
the CaMBD and thus modulates the auto-inhibitory conformation of the pump (James et 
al., 1989). 
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1.3.5 PMCA interacting partner proteins 
In addition to their role as calcium transporters, PMCAs have recently emerged as novel 
regulators of signal transduction pathways via interaction with a variety of cytoplasmic 
cellular proteins (Holton et al., 2010). These interactions involve different PMCA 
intracellular domains and regulate the activity of both PMCA and the partner proteins. 
Interactions between PMCAs and cytoplasmic partner proteins that I describe below are 
illustrated in Figure 1.11. 
A small acidic protein, 14-3-3e, interacts with the N-terminal region of PMCA. This 
interaction is isoform specific. PMCA1, PMCA3, and PMCA4 have been reported to 
interact with 14-3-3e but not PMCA2 (Rimessi et al., 2005; Linde et al., 2008).  
Several partner proteins have been found to interact with the catalytic intracellular 
domain of the pump. In this sense, Buch et al., 2005 showed that ectopically expressed 
PMCA4b interacts with calcineurin in HEK293 cells via interaction to this domain of 
PMCA4 (Buch et al., 2005). The authors demonstrated that this interaction resulted in a 
significant reduction in the activity of the calcineurin/NFAT pathway. This intracellular 
region of PMCA has also been found to interact with endogenous calcineurin in other 
cellular types such as breast cancer cells (Holton et al., 2007). Interestingly, the 
interaction of PMCA with calcineurin in breast cancer cells is isoform specific. 
Calcineurin strongly binds to the PMCA2 isoform but interacts very weakly with PMCA4 
and no interaction has been observed with PMCA1 (Holton et al., 2007). Disruption of 
the interaction between endogenous PMCA2 and calcineurin in breast cancer cells by 
over-expression of the PMCA2-interaction domain triggers calcineurin-mediated 
apoptosis and enhances paclitaxel-mediated cytotoxicity (Baggott et al., 2012). 
PMCA4/calcineurin interaction has also been found in other cell types such as 
cardiomyocytes (Wu et al., 2009), PC12 cells (Kosiorek et al., 2011), and endothelial 
cells (Holton et al., 2010).  
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The catalytic loop of PMCAs has also been reported to interact with endothelial nitric 
oxide synthase (eNOS) in endothelial cells (Holton et al., 2010). Ectopic expression of 
PMCA in endothelial cells increases the phosphorylation of the residue Thr-495 of 
eNOS leading to a significant decrease in the production of nitric oxide (NO) in 
response to acetylcholine or ionophore stimulation of the cells (Holton et al., 2010). 
These studies highlighted that eNOS activation is negatively regulated by endothelial 
PMCAs. 
Another cytoplasmic PMCA4 partner protein that has been identified to interact with the 
large intracellular catalytic loop of PMCA4 is RASSF1 (Armesilla et al., 2004). RASSF1 
is a tumour suppressor protein that is implicated in Ras-mediated apoptosis (Vos et al., 
2000). There are two major isoforms of RASSF1, RASSF1A and RASSF1C, and both 
have been shown to interact with PMCA4b in HEK293 cells through association with the 
region encompassing amino acids 652-748 of PMCA4, located in the catalytic 
intracellular loop (Armesilla et al., 2004). 
α-1 syntrophin has also been identified as an interaction partner of PMCA4b and 
PMCA1b in HEK293, cells via binding to the big intracellular loop of the pump (Williams 
et al., 2006). Interestingly, syntrophin interacts with PMCA4 and nNOS simultaneously 
to form a macromolecular complex (Williams et al., 2006). 
Regarding interactions with the C-terminal tail of PMCAs, it has been demonstrated that 
this region of the pump holds a post-synaptic density, Drosophila disc large tumour 
suppressor and Zona occludens-1 (PDZ) binding domain that interacts with cytosolic 
proteins containing PDZ domains (Di leva et al., 2008). The interaction of PDZ-
containing proteins with PMCAs is isoform-specific in many cases, for example MAGUK 
(membrane-associated gunylate kinase) proteins contain three PDZ domains that 
interact with PMCA isoforms 2b and 4b (DeMarco S and Strehler E, 2001). Likewise, 
the PDZ domain-containing protein NHERF2 (Na+/H+ Exchange Regulatory Factor 2) 
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interacts with the C-terminal tail of PMCA2b but not PMCA4b (DeMarco et al., 2002). 
Other cytoplasmic proteins reported to interact with the C-terminal tail of PMCA4b are 
CASK (calcium/calmodulin-dependent serine protein kinase) (Suhuh et al., 2003), PISP 
(PMCA-interacting single-PDZ domain) (Goellner et al., 2003), Ania-3 (Sgambato-Faure 
et al.., 2006), CLP-36 (Bozulic et al., 2007), and nNOS (neural Nitric Oxide Synthase) 
(Schuh et al., 2001). 
Although the functional significance of the interaction between PMCAs and partner 
proteins has not been completely elucidated in all cases, a large group of data supports 
that PMCAs regulate the activity of the partner proteins by establishing these 
interactions, and, in this way, PMCAs exert a pivotal role as modulators of the signal 
transduction pathways where the partner proteins are involved. In agreement with this 
concept, the interaction of PMCAs with eNOS or nNOS results in inhibition of nitric 
oxide production and thus, downregulation of NO-dependent signalling (Holton et al., 
2012; Schuh et al 2001; Oceandy et al., 2007; Mohamed et al., 2009). In the same 
context, the interaction PMCA/calcineurin inhibits calcineurin activity leading to a 
downregulation of the calcineurin-NFAT signalling pathway (Buch et al., 2005; Holton et 
al., 2007; Wu et al., 2009; Holton et al., 2010a; Holton et al., 2010b; Kisorek et al., 2011; 
Baggott et al., 2012; Baggott et al., 2014). Given the broad spectrum of implications for 
calcineurin signalling in the pathophysiology of the cell (Crabtree and Olson, 2002), the 
functional consequences of PMCA-mediated regulation of calcineurin are far reaching. 
Our group has recently reported that PMCA4 inhibits VEGF-driven angiogenesis via 
interaction with calcineurin in endothelial cells (Baggott et al., 2014). Thus, modulation 
of PMCA4 activity and, in turn, modulation of calcineurin signalling in endothelial cells, 
might be used with therapeutic purposes to treat patients suffering with diseases 
associated with abnormal angiogenesis. One of the lines of research under investigation 
in our laboratory focuses on the identification of selective inhibitors of PMCA4 function, 
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and the work presented in this thesis has examined the consequences of 
pharmacological-mediated inhibition of PMCA4 on VEGF-driven angiogenesis.  
 
 
 
Figure 1.11 PMCA interacting partner proteins (adapted from Di Leva et al., 2008). eNOS, 
endothelial nitric oxide synthase; RASSF1, Ras-associated factor 1; nNOS, neuronal nitric oxide 
synthase; CASK, calcium/calmodulin-dependent serine protein kinase; MAGUK, membrane-
associated gunylate kinase; PISP, PMCA-interacting single-PDZ domain; NHERF2, Na+/H+ 
Exchange Regulatory Factor 2; PDZ, post-synaptic density, Drosophila disc large tumour 
suppressor and Zona occludens-1.  
 
1.3.6 PMCA inhibitors  
Initially, lanthanium (La3+) and vanadate were used to inhibit PMCA4. They are general 
inhibitors of all P-type ATPases as they both inhibit ATPase activity by competing for 
the ATP binding site in the catalytic domain of all P-type ATPases (Quist et al., 1975; 
Cantley et al., 1977; Barrabin et al., 1980). Therefore, lanthanium or vanadate could not 
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be used as a specific inhibitor for PMCA4 in this study as they would act on any P-type 
ATPase. 
 As PMCA4 ATPase activity is calmodulin dependent, it can therefore be inhibited by 
calmodulin antagonists, such as calmidazolium, which inhibits PMCA4 by direct binding 
to calmodulin, or by interacting with its binding sites (Gietzen et al., 1982). 
Calmidazolium could not be used as a PMCA4 specific inhibitor as it would also inhibit 
the other members of the PMCA family and all calmodulin-dependent proteins such as 
calmodulin-dependent protein kinase (CaMK), calcineurin, calmodulin-dependent 
phosphodiesterase (PDE) and others (Sunagawa et al., 1998; Mukai et al., 1991).  
Polypeptides called caloxins have been used to inhibit PMCA by binding to the 
extracellular domains of the pump. The extracellular sequences of all PMCA isoforms 
are extremely well conserved and it is therefore difficult to achieve inhibition of a specific 
isoform. Caloxin 1c2 has shown high specificity to PMCA4, but it also inhibits other 
isoforms with lower affinity (Strehler et al., 2007; Szewczyk et al., 2007; Pande et al., 
2011).  
In many studies eosin and its analogue carboxyeosin have been reported as potent 
inhibitors for all PMCA isoforms; they act by interfering with the binding of ATP to a 
conserved site found in all ATPases (Gatto et al., 1993; Shmigol et al., 1998). 
In summary, although all these compounds inhibit PMCA4, they did not show more 
potency in inhibiting PMCA4 activity compared with other ATPases. However, 
Mohamed et al., 2013, recently identified a small molecule which strongly inhibits 
PMCA4 and no other PMCA isoforms or other ATPases (Mohamed et al., 2013). To 
identify this molecule the authors screened a library of 1280 medically optimised drug-
like molecules against PMCA4 activity and found that aurintricarboxylic acid (ATA) has 
a high inhibitory effect for PMCA4 at a very low concentration (Mohamed et al., 2013). 
ATA is a polyaromatic carboxylic acid derivative with a molecular weight of 422.345 
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g/mol (Figure 1.12). ATA easily polymerizes in aqueous solution forming a stable free 
radical (Kuban-Jankowska et al., 2016). Although ATA has been reported to be soluble 
in aqueous solutions (Green, 1990), the solubility of ATA in organic solvents is around 
ten times higher than in water (Green, 1990). Cells in culture were treated with a 
minimal volume of ATA solution to avoid dilution of growth factors in the medium that 
could result in damage of cells. To achieve this, a very high concentrated stock of ATA 
was prepared. To maximize solubility of ATA in this concentrated stock DMSO was 
used as a solvent instead of water. As DMSO was used as a vehicle in the preparation 
of our stock solution, control cells in this work were treated with DMSO to be sure that 
any observed effects were due to the action of ATA and not to interference caused by 
the vehicle.   
As ATA has been shown to inhibit the calcium extrusion activity of PMCA4 strongly and 
selectively at concentrations that do not exert any effect on the activity of PMCA1 or 
other major calcium pumps (such as SERCA and Na+/K+ ATPase) (Mohamed et al., 
2013) and PMCA4 has been reported to regulate the calcineurin/NFAT pathway, we 
decided to investigate in this work whether ATA-mediated inhibition of PMCA4 
enhances the activity of the calcineurin/NFAT pathway and thus, calcineurin-dependent 
angiogenesis. Recently ATA was shown to inhibit the activity of PMCA4 in vivo using a 
mouse model of cardiac hypertrophy (Mohamed et al., 2016). In this work, the authors 
demonstrated that injection into mice of ATA at 5 mg/kg/day for 2 weeks, reversed 
cardiac hypertrophy without causing any harmful side-effects on the animals (Mohamed 
et al., 2016). Likewise, Zhang et al., 2013, demonstrated the potential of using ATA at 
20 mg/kg/day to reduce experimental autoimmune encephalomyelitis in mouse animal 
models without observing any toxic effects (Zhang et al., 2013). 
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These studies indicate that the effects of ATA in pathological conditions can be tested in 
vivo using pre-clinical animal models. However, if this compound is to be translated into 
clinical applications in humans, ADMET studies need to be carried out to assess the 
feasibility of its use or whether more specific, non-toxic versions of ATA are required. 
 
 
Figure 1.12 Structure of aurintricarboxylic acid (adapted from Kuban Jankowska et al., 
2016). Structure of aurintricarboxylic acid (ATA) showing chemical groups and atomic formula. 
ATA has been described as a strong inhibitor of PMCA4 calcium extrusion activity. 
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CHAPTER 2 
Aims and Hypothesis 
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2. Aims and hypothesis  
VEGF-mediated activation of the calcineurin/NFAT signalling pathway plays a pivotal 
role in the regulation of pathological and physiological angiogenesis (Armesilla et al., 
1999; Hernandez et al., 2001). Our group has previously demonstrated that PMCA4 
downregulates the activation of the calcineurin/NFAT pathways in endothelial cells 
stimulated with VEGF and, in doing so, inhibits VEGF-induced pro-angiogenic signalling 
(Baggott et al., 2014). The recent identification of aurintricarboxylic acid (ATA) as a 
strong inhibitor of PMCA4 (Mohamed et al., 2013) prompted us to hypothesise that 
inhibition of PMCA4 with ATA will enhance VEGF-induced angiogenesis.  
To test this hypothesis we have established the following aims for this thesis:  
1) To determine the activity of the calcineurin/NFAT pathway in endothelial cells 
when PMCA4 activity is inhibited by treatment with ATA. 
2) To determine the effect of PMCA4 inhibition by ATA on the expression of VEGF-
responsive, pro-angiogenic, NFAT-target genes.  
3) To examine the effect of ATA-mediated inhibition of PMCA4 on the interaction 
between PMCA4 and calcineurin in endothelial cells. 
4) To investigate the effect of PMCA4 inhibition by ATA on endothelial cell motility. 
5) To determine the effect of ATA-mediated inhibition of PMCA4 on endothelial cell 
tubular morphogenesis. 
6) To examine the effect of ATA on the viability of endothelial cells. 
7) To determine the effect of ATA on the interaction of PMCA4 with endothelial nitric 
oxide synthase (eNOS). 
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Figure 2.1 Hypothesis tested in this study. Inhibition of PMCA4 with ATA enhances 
VEGF-induced angiogenesis. A) Interaction of PMCA4 with calcineurin leads to 
downregulation of calcineurin activity and, in doing so, attenuates calcineurin-mediated 
angiogenesis in response to VEGF. B) Inhibition of PMCA4 with ATA reverses the negative 
effect exerted by PMCA4 on calcineurin, which can be fully activated in response to VEGF 
stimulation leading to an improvement in the associated pro-angionenic processes. 
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CHAPTER 3 
Materials and Methods 
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3.1 Tissue culture 
Cell culture procedures were carried out under aseptic conditions using a class II 
microbiological safety cabinet (BioMAT 2, CAS, UK) sterilised with 70% ethanol (Sigma-
Aldrich, UK) and 1% Trigene (Sigma-Aldrich, UK) solution, to prevent the risk of 
contamination of cells. All solutions required for tissue culture were warmed to room 
temperature prior to use. Cells in culture were routinely passaged to maintain and 
amplify cells. To do this, following aspiration of the medium from the culture flask, cells 
were washed with 1x phosphate buffered saline (PBS 1x) and detached with a 0.25% 
trypsin-EDTA solution. Cells were checked under the microscope to ensure they were 
detached, and fresh complete media was added to neutralize the trypsin. The contents 
of the flask were transferred into a sterile universal tube and centrifuged at 1200 rpm for 
5 minutes. After removing the supernatant, pelleted cells were re-suspended in fresh 
medium and transferred to tissue culture flasks of required size. Cells were then 
incubated at 37ºC, 5% CO2. 
3.1.1 Recovering cells from liquid nitrogen 
A cryovial with 3 x 106 cells frozen in a solution of 10% dimethyl sulfoxide (DMSO) in 
fetal bovine serum (FBS) was carefully removed from the liquid nitrogen storage tank 
and thawed at 37ºC. The cell solution was diluted 1:10 in tissue culture medium to 
prevent damage to cells and centrifuged at 1200 rpm for 5 minutes. The supernatant 
was carefully removed. The cell pellet was re-suspended in fresh tissue culture medium 
and transferred to T175 tissue culture flask. Cells were then cultured at 37ºC, 5% CO2. 
3.1.2 Human Umbilical Vein Endothelial Cells (HUVECs) 
HUVECs purchased from TCS Cellworks were grown in tissue culture flasks pre-coated 
with 0.1% gelatin in Endothelial Cell Growth Medium (ECGM, PromoCell) supplemented 
with 1% penicillin/streptomycin/amphotericin B (Sigma-Aldrich) and ECGM-supplement 
mix (Promocell, UK) containing: 2% FBS, 0.4% endothelial cell growth supplement, 0.1 
54 
 
ng/ml epidermal growth factor (recombinant human), 1 ng/ml basic fibroblast growth 
factor (recombinant human), 90 µg/ml heparin, and 1 µg/ml hydrocortisone. HUVECs 
between passages 5 and 8 were used for experiments. 
3.1.3 Human Embryonic Kidney 293A Cells (HEK293A) 
HEK293A cells were cultured in tissue culture flasks pre-coated with 0.1% gelatin in 
Dulbecco's Modified Eagle Medium (DMEM) (Sigma-Aldrich, UK) supplemented with; 
10% FBS, 1.73 mM L-glutamine, 1% penicillin/streptomycin/amphotericin B (Sigma-
Aldrich, UK). HEK293A were used for amplification of adenoviral vectors (see section 
3.3.2). 
3.1.4 Mouse Lung Endothelial Cells (MLECs)  
Purified MLECs were plated on tissue culture plates pre-coated with 0.1% gelatine and 
cultured in MLEC medium consisting of DMEM/F-12 medium (Sigma-Aldrich, UK) 
supplemented with 20% FBS, 0.1 mg/ml heparin sodium salt from porcine intestinal 
mucosa (Sigma-Aldrich, UK), 4mM L-glutamine, 250 µg/ml endothelial cell growth 
supplement (AbD serotec, UK), and 1% penicillin/streptomycin/amphotericin B (Sigma-
Aldrich, UK). MLECs were used at very early stages (either when freshly isolated cells 
reached 80% confluency or after one passage). 
3.1.4.1 Isolation of Mouse Lung Endothelial Cells (MLECs) 
Lungs removed from 6-8 week old wild-type (PMCA4+/+) and knockout (PMCA4-/-) mice 
(Schuh et al., 2004) were a generous gift from Dr Elizabeth Cartwright (Cardiovascular 
Research Group, University of Manchester, Manchester, United Kingdom). Lung 
samples were first transferred to DMEM-F12 serum-free medium, and then washed in 
70% ethanol for 5 seconds. Traces of ethanol were removed by placing lungs in MLEC 
medium for 30 seconds. Lungs were then minced into a paste, and digested in 10 ml of 
a 440 units/ml solution of Type I collagenase (Gibco, UK) for exactly one hour at 37ºC. 
Freshly prepared collagenase was used for each round of MLEC isolation. To prepare 
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collagenase digestion solution, 0.1 g Type I collagenase was added to 25 ml of PBS 1x. 
The mixture was incubated at 37ºC for 1 hour to maximise solubility of collagenase, and 
then 25 ml more of PBS were added to generate a final concentration of collagenase 
440 units/ml. The solution was sterilised by filtration and pre-warmed at 37ºC before 
use. Lung digestion was stopped by adding 10 ml of MLEC medium and then the tissue 
was disrupted by passing everything through a 19 gauge needle four times. Remaining 
chunks of lungs were removed by filtering the solution through a 70 μm cell strainer. 
The filtrate was added to a tube containing 20 ml of MLEC medium. Lung cells were 
collected by centrifugation for 10 minutes at 1200 rpm. The supernatant was removed 
carefully, and the pellet re-suspended in 10 ml of MLEC medium and plated onto 
Primaria™ 100 mm tissue culture dishes (BD biosciences, UK) that had been pre-
coated for at least two hours with 0.1% gelatin and 0.1 mg/ml fibronectin from bovine 
plasma (Sigma-Aldrich, UK). Cells were incubated at 37°C, 5% CO2 overnight. The 
following day, the mixed population of cells was subjected to negative selection in order 
to remove macrophages and other immune cells that display the FcγIII/II receptor. For 
this purpose, the medium was aspirated and cells were washed three times with PBS 1x 
to completely remove cells in suspension. Then 5 ml of fresh MLEC medium were 
added and cells were incubated at 4°C for 20 minutes. After incubation, MLEC medium 
was replaced with 3 ml of a 1.7 µg/ml solution of purified rat anti-CD16/CD32 (FcγIII/II 
receptor) antibody (BD Biosciences, UK) in PBS 1x, and cells were further incubated at 
4°C for 30 minutes with regular rotation of the plate, to ensure that the whole surface of 
the plate was covered with antibody solution at all times. The antibody solution was 
removed after incubation. Cells were washed once with PBS 1x, and 3 ml of magnetic 
beads conjugated anti-rat IgG antibody solution (Dynabeads, Invitrogen) (6.7x106 
beads/ml in MLEC medium) were added to the plate that was incubated at 4°C for 30 
more minutes with gentle agitation. Cells were washed three times with PBS 1x, 
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detached with trypsin and re-suspended in 15 ml of MLEC medium. The solution was 
transferred to a centrifuge tube that was then placed in a magnetic holder for 7 minutes 
to direct macrophages attached to magnetic beads to the wall of the tube that was in 
contact with the magnet. Cells in suspension were carefully pipetted out of the tube 
while avoiding to taking any beads, and placed into a pre-coated 10 mm tissue culture 
dish. Plates were incubated at 37ºC, 5%CO2. MLEC medium was changed every day 
until colonies of approximately 20-30 cells were visible under the microscope. The cells 
were cultured normally for 5-7 days. The variability of incubation time is required in 
different isolation experiments was probably due to differential digestion with Type I 
collagenase, or minimal variations in the strength applied when the tissue was 
disaggregated by passing through a 19-gauge needle. Also, minor differences might be 
caused by small variation in the length of time between harvesting lungs and platting 
cells, or small differences in age of the mice. No difference in MLEC recovery were 
observed when using mice of different gender. Endothelial cells were then selected 
using an antibody directed against the endothelial cell marker ICAM-2 (CD102). The 
same procedure described above for negative selection was performed in this step, 
except that a purified rat anti-CD102 antibody (BD Biosciences, UK) was used to select 
the cells, and that in this case, cells in suspension were discarded whereas magnetic 
beads with attached endothelial cells were recovered, resuspended in 10 ml of MLEC 
medium and plated in pre-coated 100 mm tissue culture dishes. Cells were incubated at 
37ºC, 5% CO2 and medium replaced every day until cells reached confluency. The 
purity of the culture in endothelial cells was monitored using flow cytometry by 
determining the percentage of cells in the population expressing the endothelial cell 
marker ICAM-2 (CD102). 
Deficiency of PMCA4 in cells isolated from PMCA4-/- mice was checked by qRT-PCR 
and western blot. 
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3.1.5 Maintenance of cell cultures 
Cells were routinely monitored for any changes in the growth medium and cell 
population. The medium was changed every 1-2 days or when there was a change in 
the colour of the medium indicating a drop in pH. Cells were incubated at 37ºC, 5% CO2 
until reaching confluency. 
3.1.6 Counting cells  
To determine the number of cells in a cell suspension, an aliquot of 10 µl of mixed cell 
suspension was placed in a haemocytometer. Cells were counted under the 
microscope. The number of cells in 1 ml of the suspension is calculated by multiplying 
the number of cells counted in the haemocytometer x 104. 
3.1.7 Freezing cells 
Following trypsinisation, the cell suspension (3 x 106 cells) was centrifuged at 1200 rpm 
for 5 minutes. The supernatant was discarded and the pellet was re-suspended in 1 ml 
of freezing medium (90% FBS, 10% DMSO), transferred to a labelled cryovial (Nalgene 
Cryoware™ Labware, Roskilde, Denmark) and stored at -80ºC for 2 days to ensure 
slow freezing before transferring vials to a liquid nitrogen storage tank (-196ºC). DMSO 
was used in the freezing medium as a cryoprotective agent. Initial freezing at -80ºC for 
2 days with subsequent transfer to liquid nitrogen guaranteed a slow cooling process 
that reduces the risk of ice crystal formation and diminishes cell damage during the 
freezing process.  
3.2 Cell stimulation 
Where specified, some experiments required cell stimulation. To do this cells were 
washed with PBS 1x to completely remove any remaining medium containing serum 
and cells were then incubated in the corresponding serum-free medium with 0-2% FBS 
without any supplementary growth factors for the required time.  
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HUVECs and MLECs were stimulated with VEGF 25 ng/ml (Peprotech). To prepare 
VEGF solution, 10 µg lyophilized form of VEGF was dissolved in 400 µl of PBS 1x. 5 µl 
of this stock solution were added to 5 ml of culture medium to make a final 
concentration of VEGF 25 ng/ml. 
HUVECs were stimulated with bFGF 50 ng/ml (Peprotech). To prepare this stock 
solution, 10 µg of bFGF was added to PBS 1x (400 µl). 10ul of stock bFGF solution 
were added to 5 ml of culture medium to make a final concentration of bFGF 50 ng/ml. 
HUVECs and MLECs were treated with ATA at 250 nM. To prepare an ATA stock 
solution, 4 mg of ATA powder (Sigma-Aldrich, UK) were added to 10 ml of DMSO. The 
mixture was mixed thoroughly, and then diluted 1:5 in DMSO.  6.25 ul of this stock 
solution were added to 5 ml of the corresponding cell culture medium to generate a final 
concentration of 250 nM. 
3.3 Transfection of endothelial cells using replication-deficient adenoviral vectors 
3.3.1 Adenoviruses used in this study 
Viruses (Ad-NFAT-Luc and Ad-LacZ) used for this study were kindly provided by Dr 
Delvac Oceandy and Dr Elizabeth J. Cartwright from the Division of Cardiovascular 
Sciences, University of Manchester, Manchester Academic Health Sciences Centre, 
Manchester, UK. Replication-deficient adenovirus Ad-NFAT-Luc harbours an NFAT-
dependent, luciferase-based reporter vector encoding luciferase. The expression of the 
luciferase gene in this vector is controlled by 3 NFAT-binding motifs placed upstream of 
a minimal promoter region. Generation of this vector has been previously described 
(Baggott et al., 2014). This vector was used to monitor the activity of the 
calcineurin/NFAT signalling pathway in endothelial cells. Replication-deficient 
adenovirus Ad-LacZ encodes the β-galactosidase protein and was used as a control 
(Baggott et al., 2014).  
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Replication-deficient adenovirus Ad-ID4 encodes a Flag-tagged version of the fragment 
encompassing aminoacids 428 to 651 of human PMCA4 that corresponds to the 
domain implicated in the interaction with calcineurin (Buch et al., 2005). This vector was 
generated in our laboratory and its generation has been previously described (Baggott 
et al., 2014). This adenovirus was used to express the polypeptide Flag-PMCA4(428-
651) in endothelial cells to disrupt the interaction between endogenous PMCA4 and 
calcineurin as it has been reported (Baggott et al., 2014). 
A schematic representation of the features of these 3 vectors is shown in Figure 3.1. 
             
Fig 3.1 Main features of the adenoviruses used in this study. Ad-NFAT-Luc is an NFAT-
dependent adenovirus encoding the protein Luciferase. Luciferase expression is driven by 
NFAT ocupancy of three NFAT binding sites placed in tandem upstream of the minimal 
promoter of the timidine kinase (tk) gene. In Ad-LacZ, the expression of -galactosidase is 
controlled by the promoter of cytomegalovirus (CMV). Ad-ID4 encodes a Flag-tagged version of 
the region 428-651 of human PMCA4b that corresponds to the domain of PMCA4b that 
interacts with calcineurin. Expression of Flag-PMCA4(428-651) in this vector is driven by the 
CMV promoter. 
 
 
3.3.2 Amplification of adenoviruses 
Low passage number HEK293A cells were cultured in T175 tissue culture flasks as 
described. Secondary stock of adenovirus was generated by infection of HEK293A cells 
with a primary stock of virus (50 µl/flask) for 3-5 days until all cells showed symptoms of 
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the cytotoxic effect of adenovirus infection (cells become rounded and detached). The 
virus was collected by transferring cells/medium to falcon tubes. Medium with cells was 
centrifuged at 1500 rpm for 5 minutes at room temperature. The supernatant was 
discarded with great care and the pellet was washed in 5 ml of PBS 1x. Cells were re-
centrifuged as above and the pellet finally re-suspended in 0.5 ml/flask of PBS 1x. Virus 
was stored at -80ºC or processed for further amplification.  
Tertiary stock of the virus was produced by infection of confluent HEK293A cells with a 
secondary stock of virus generated in the previous step (50 μl/flask). Cells were 
incubated with virus until all cells had become rounded and detached. Cells containing 
virus were collected by centrifugation, washed with PBS 1x as described above, and 
resuspended in 0.5 ml/flask of PBS. Purification of the virus was performed by adding 
an equivalent volume of chloroform. The solution was mixed continuously by inversion 
for 5 minutes and then centrifuged for 15 minutes at 3000 rpm at room temperature. 
The top phase (containing the virus) was collected with extreme care and stored at -80°.  
To determine the number of adenovirus particles in the tertiary stock of the virus, 
HEK293A cells were seeded in at 5 x 103 cells/well in 96-well tissue culture plates, and 
incubate overnight at 37ºC. The following day the medium was removed and replaced 
with 100 µl of serially diluted adenovirus stocks (diluted in DMEM medium), and cells 
incubated for 24 hours. Each dilution point was analysed in triplicate. After this period, 
medium containing virus was removed and 100 µl of fresh DMEM was added to each 
well. The medium was changed on day 4 and plaque formation was monitored each 
day. On day 8 following infection final dilution which shows plaque formation were taken 
as the endpoint from the assay. Appendix 4 shows detailed correlation of virus dilution 
and number of infectious adenovirus particle (Pickard 2007).  
3.3.3 Adenoviral Infection 
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To determine the activity of the calcineurin/NFAT pathway, HUVECs were cultured in 6-
well tissue culture plates at a density of 3 x 105 cells/well, and then infected with Ad-
NFAT-Luc at a MOI=50, for 48 hours at 37°C, 5% CO2. After this period, medium 
containing virus was removed, cells were washed with PBS 1x twice, and then 
incubated overnight in ECGM basal medium supplemented with 0.5% FBS for serum-
starvation of the cells. The following morning cells were stimulated as indicated and 
luciferase activity determined. 
To disrupt the interaction between PMCA4 and calcineurin, HUVECs seeded in T-75 
tissue culture flasks at a density of 2.5 x 106 cells/flask were infected with Ad-LacZ or 
Ad-ID4 at a MOI=150 for 72 hours, and used for migration and western blot assays as 
described in later sections. 
3.4 Protein Determination Assays 
3.4.1 Collection of total proteins  
 
Total proteins were collected from whole cells by washing the cells with PBS 1x and 
directly lysing the cells in NuPAGE® LDS sample buffer (Life Technology, UK) 
containing 0.05% beta-Mercaptoethanol. As a reference, cells growing in a 6 well-plate 
were lysed in 100 µl of PAGE-LDS buffer per well. Cell lysate was heated at 100°C for 
10 minutes to solubilise DNA and then cooled down on ice before storing at -20°C until 
used. 
3.4.2 Isolation of plasma membrane-associated proteins  
 
To determine the interaction between PMCA4 and calcineurin proteins in the plasma 
membrane, HUVECs were seeded at a density of 4 x 106 cells/flask in a T-75 tissue 
culture flask and incubated at 37°C, 5% CO2.  The following day, cells were serum- 
starved for 3 hours in ECGM basal medium (Promocell) without serum, and stimulated 
with VEGF (25 ng/ml) in the presence or absence of 250 nM aurintricarboxlic acid (ATA) 
for 4 hours. To isolate membrane-associated proteins we used a ProteoExtract 
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Subcellular Proteome Extraction Kit (Calbiochem) according to the manufacturer’s 
instruction. Briefly, medium was carefully removed and cells washed with 5 ml of ice-
cold wash buffer with gentle agitation at 4°C for 5 minutes. After washing, the buffer was 
completely removed. Ice-cold extraction buffer I was prepared by mixing 2 ml of 
extraction buffer with 5 µl of protease inhibitor cocktail, and added into the flasks. It was 
ensured that the buffer covered all the surface of the flask, and cells were incubated for 
10 minutes with gentle agitation at 4°C. This buffer extracted only cytoplasmic proteins 
as indicated by the manufacture. Lysate containing cytoplasmic proteins was discarded. 
Ice-cold extraction buffer II was prepared by mixing 2 ml extraction buffer II with 5 µl 
protease inhibitor cocktail, and added into the flasks making sure that all the surface of 
the flask was covered with buffer. Cells were incubated in buffer II for 30 minutes at 4°C 
with gentle agitation. This buffer extracted membrane-associated proteins. The buffer 
containing membrane-associated protein was recovered and spun at 13000 rpm for 2 
minutes to clear debris. Protein sample was transferred to an Amicon Ultra-0.5 
centrifugal filter device, and concentrated by centrifugation at 14000 rpm for 30 minutes 
at 4°C. Protein concentration in the samples was measured using a BCA protein assay, 
and equal amount of proteins were analysed by western blot. 
3.4.3 Protein concentration measurement  
To determine the concentration of proteins in protein lysates we used a BCATM Protein 
Assay Kit (Thermo Scientific) according to the manufacturer's recommendations. Briefly, 
serial dilutions of Bovine Serum Albumin (BSA) protein were freshly prepared for each 
assay and used as a reference. The assay was performed by preparing a 50:1 mixture 
of Pierce BCA reagent mix A and B respectively. 200 µl of Reagent A:B mixture were 
added to 25 µl of  sample (or BSA standard) and incubated at 37°C for 20 minutes in 
the dark. Absorbance of samples was read at 540nm using a multiwell plate reader 
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spectrophotometer (Thermo LabSystems) and protein concentration of the samples was 
calculated using the reading of BSA standard samples as a reference. 
3.5 Immunoprecipitation (IP)  
To determine the interaction of PMCA4 protein with calcineurin and eNOS in VEGF-
stimulated HUVECs, we carried out immunoprecipitation assays using a Pierce™ Co-
Immunoprecipitation kit (Sigma-Aldrich, UK). HUVECs were cultured in T175 tissue 
culture flasks at 37°C, 5% CO2 until reaching confluency. Confluent cells were serum-
starved in ECGM medium without any serum for 3 hours, and then stimulated with 
VEGF (25 ng/ml) in the presence or absence of ATA (250 nM). After treatment, cells 
were lysed using ice-cold IP Lysis/Wash buffer and the lysate was transferred to an 
eppendorf tube and kept at 4°C on ice until use. For immunoprecipitation of the 
PMCA4/calcineurin complex, 15 µl of anti-calcineurin A monoclonal antibody (Sigma-
Aldrich, UK) was coupled to 100 µl of AminoLink plus coupling Resin (Pierce) by 
incubation in ‘’Coupling buffer 1x’’ (Pierce) with rotation for 120 minutes at room 
temperature. The resin-antibody complex was washed twice with ‘’Wash Buffer’’ 
provided in the kit, and then incubated with 4 mg of protein lysate overnight, at 4°C with 
rotation. The following day, the resin was extensively washed with ‘’Wash buffer’’ and 
finally, immunoprecipitated proteins were eluted with 60 µl of ‘'Elution Buffer''. 20 µl of 
4x NUPAGE sample buffer containing 0.05% beta-mercaptoethanol were added to the 
samples. 
For immunoprecipitation of the PMCA4/eNOS complex, the same procedure was 
followed except that 10 µl of the anti-PMCA 5F10 monoclonal antibody (Abcam) was 
used for immunoprecipitation. 
3.6 Western Blot  
3.6.1 Protein separation by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE)  
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A mixture of proteins was separated according to size by SDS-PAGE using a standard 
twin-plate mini gel unit system (SCIE-PLAS). A resolving gel solution with a percentage 
of acrylamide/bis-acrylamide between 6% and 12% was prepared depending on the 
size of the protein to be detected. This was added first to a gel casting device between 
two glass plates. After polymerisation, a stacking gel solution was placed on top of the 
resolving gel and a comb was immediately inserted on the top of the stacking gel 
solution to form wells required for loading of protein samples. A detailed protocol 
describing the reagents and amounts used in the preparation of the gel solutions has 
been included in ‘’Appendix 1’’ at the end of this thesis. 
Protein samples were heated at 100°C for 2 minutes, and cooled down on ice very 
briefly before loading. 10 µl of BLUeye protein ladder (GeneFlow, UK) or 10 µl of 
ProtomarkersTM (National diagnostics) pre-stained protein ladder were loaded as 
markers of protein molecular weight. 
Gels were run in Tris-Glycine buffer (0.025M Tris, 0.192M Glycine, 0.1% SDS) at 200V 
until the mixture of protein markers was clearly separated. 
3.6.2 Protein blotting to PVDF membrane 
Proteins were transferred from the gel to a polyvinylidene difluoride (PVDF) membrane 
using a wet-transfer blotting apparatus (Invitrogen) according to the following procedure. 
Prior to set up of the blotting transfer equipment, a PVDF membrane of the size of the 
PAGE resolving gel was hydrated with pure methanol and subsequently washed in 
dH2O to remove methanol traces. Protein transfer was carried out by placing the gel 
and membrane between a ‘'sandwich'' formed by several layers of Whatman 3 MM 
chromatography paper and foam sponges, both soaked in transfer buffer (0.025M Tris, 
0.192M Glycine, 20% methanol). 
Protein transfer was carried out at 35V for 90 minutes with all the components 
immersed in transfer buffer. After completion of the process, the membrane was 
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separated from the gel and successful transfer was verified by visualisation of the pre-
stained protein markers in the membrane.  
3.6.3 Protein Detection  
After protein transfer, membranes were incubated in a 5% solution of skimmed milk in 
Tris Buffered Saline (TBS) 1x for 1 hour with agitation, in order to prevent non-specific 
binding of primary and secondary antibodies to the membrane. After completing this 
blocking step, the milk solution was removed and the membrane briefly washed with 
TBS-T (TBS-0.05% Tween 20). Appendix 2 shows a detailed description of the primary 
antibodies and conditions used in this study. For detection of Flag-tagged proteins, the 
membrane was incubated with a 1:2000 solution of anti-Flag M2 monoclonal HRP 
conjugated antibody (Sigma-Aldrich, UK) for 3 hours, at room temperature, washed in 
TBS-T five times for 5 minutes each, and developed following the ECL method 
described below. 
In all other cases, membranes were incubated overnight, at 4°C, with agitation, in a 
solution of a primary antibody recognising specifically the protein to be detected diluted 
in TBS-T (Appendix 3). The following day, the solution containing primary antibody was 
removed, and membranes washed five times with TBS-T for 5 minutes each. Primary 
antibodies bound to the protein were detected by incubation for 3 hours at room 
temperature with a solution of a HRP-conjugated secondary antibody recognising 
specifically IgGs from the host used to produce the primary antibody. Unbound 
secondary antibody was removed by washing the membrane five times for 5 minutes 
each with TBS-T. 
Finally, membranes were developed using an EZ-ECL chemiluminescence detection kit 
(GeneFlow, UK) by mixing ‘’Solution A’’ and ‘’Solution B’’ from the kit at a 1:1 ratio, and 
incubating the membrane in the resulting solution for 1 minute. Signal was detected by 
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exposing the membrane to Kodak BioMax MS auto-radiographic film (Sigma-Aldrich, 
UK) in dark conditions for different periods of time and subsequent development. 
Protein levels were quantified by digital scanning of films and detection of band intensity 
using ImageJ software (National Institute of Health, USA). 
3.7 Quantification of RNA gene expression 
3.7.1 RNA isolation and purification 
Quantitative real time-PCR analysis was used to determine the successful knockout of 
PMCA4 in isolated MLECs. PMCA4+/+ and PMCA4-/- cells were plated at a density of 4 x 
105 cells/well in pre-coated 6-well tissue culture plates and incubated at 37°C, 5% CO2 
for 24 hours. The medium was removed and cells washed in PBS 1x. Total RNA was 
isolated using a RNA purification kit (Norgen, Canada). Cells were lysed using 300 μl of 
buffer RL and lysate stored at -80°C or processed immediately for RNA isolation. 
Absolute ethanol (100%) was added to the lysate and the mixture vortexed for 10 
seconds at room temperature. Then the solution was passed through spin-columns by 
centrifugation at 13000 rpm for 60 seconds. 100 µl of a DNase I solution (Norgen, 
Canada) were added to the columns and incubated for 15 minutes to remove any DNA 
present in the sample. After this time, the DNAse I solution was removed by 
centrifugation and the columns thoroughly washed with wash solution. RNA was eluted 
by addition of 50 μl of RNA elution buffer directly to the dry columns and incubation for 2 
minutes at room temperature. Purified total RNA was then collected by centrifugation at 
room temperature for 2 minutes at 2000 rpm, followed by centrifugation for 1 minute at 
13000 rpm.  
3.7.2 RNA Quantification 
RNA concentration and quality of each sample was measured using a NanoDrop 2000 
spectrophotometer (Thermo Scientific, UK). The ratio of absorbance at 260nm and 
280nm was used to assess the purity of RNA in the sample. 
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3.7.3 Complementary DNA (cDNA) synthesis 
A high capacity cDNA reverse transcription kit (Applied Biosystems, UK) was used to 
synthesise cDNA from total RNA isolated in section 3.7.1. After RNA quantification, 
samples were diluted to 500 ng of total RNA in a final volume of 10 μl with nuclease-
free water (Promega, UK). 10 µl of total RNA solution (50 ng/µl) were mixed with 10 µl 
of a 2x Reverse Transcription mixture containing 2x Retro Transcription buffer, 8mM 
dNTP mix, 2x random primers, and RNAse inhibitor (2 units/µl). This 2x RT master mix 
was mixed with each sample to make a final volume of 20 µl. Reverse transcription was 
carried out in a thermal cycler (PTC-200 Peltier Thermal Cycler, MJ Research) using 
the following conditions; 25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 minutes. 
After this time, the cDNA was placed on ice for immediate use or stored at -20ºC for 
long term storage.  
3.8. Quantitative real-time PCR (qRT-PCR)  
The quantification of gene-specific mRNA expression was determined by qRT-PCR 
using TaqMan Gene Expression Assays (Thermo Scientific, UK) with FAM reporter. The 
assay includes a pre-designed primer-pair and a unique probe for each target under 
investigation. For each test, the cDNA reaction was diluted 1:4 with nuclease-free water 
and 5.6 µl of this dilution added to a reaction mix consisting of 10 µl of a 2x realtime 
qRT-PCR master mix (Thermo Fisher), 1 µl of TaqMan Gene Expression assay-and 3.4 
µl PCR grade nuclease-free water to make a final volume of 20 µl. A negative control 
sample that contained 5.6 µl of nuclease-free water instead of cDNA solution was 
included in the assay to verify the fidelity of the PCR amplification. The reactions were 
prepared in MicroAmp® fast optical 96-well reaction plates (Applied Biosystems, UK). 
After setting up the reaction, the plate was sealed with an optically clear seal, gently 
tapped to remove any air bubbles and placed on a 7500 Fast Real-Time PCR System 
(Applied Biosystems, UK). PCR cycling conditions consisted of an initial enzyme 
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activation step at 95ºC for 10 minutes, followed by denaturation at 95ºC for 15 seconds 
and annealing and extension at 60ºC for 1 minute for 40 cycles. Data were exported to 
GraphPad Prism for statistical analysis. The expression of the murine GAPDH gene 
was determined in parallel as control. 
3.9 Luciferase reporter assay 
To study the effect of ATA on the activity of the calcineurin/NFAT signalling pathway, 
primary HUVECs were seeded at a density of 3 x 105 cells/well in a 6-well tissue culture 
plate the day before viral infection. The following day, cells were infected with Ad-NFAT-
Luc (an NFAT-dependent luciferase-based reporter vector) at a multiplicity of infection 
(MOI) = 50 and cells were incubated at 37ºC, 5% CO2 for 48 hours. After infection, 
medium containing virus was removed and cells were serum-starved in ECGM medium 
containing 0.5% serum for 16 hours. The following day, cells were treated with ATA 
(250 nM) or DMSO for one hour and then stimulated with VEGF (25 ng/ml) for 6 hours. 
Stimulated cells were washed once with PBS and lysed in 60 µl of Cell Lysis Reagent 
1x (Promega, UK) at room temperature for 10 minutes. Luciferase activity in the lysate 
was determined in a SIRIUS Luminometer V3.1 (Berthold detection systems, UK) by 
mixing 20 μl of the cell lysate and 100 μl of ‘’Luciferase Assay Substrate’’ from a 
Luciferase Assay System Kit (Promega, UK) and measuring the relative light units 
(RLU) produced after 30 seconds. 
3.10 Wound healing migration assay 
Cell migration assays of HUVECs and MLECs were carried out using the “CytoselectTM 
24-well wound healing assay kit” (Cell Biolabs). HUVECs were plated at a density of 7 x 
105 cells/well in 0.1% gelatine pre-coated 24-well cell culture plates (COSTAR, UK), and 
a 0.9 mm gap was created using inserts from the assay kit. Cells were incubated for 24 
hours at 37°C, 5% CO2 for attachment. The following day, gap creators were removed 
and cells corresponding to time zero (t=0) were stained with a 0.6% crystal 
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violet/0.025% ammonium oxalate/5% ethyl alcohol solution (Sigma-Aldrich, UK) for 15 
minutes at 37°C. Excess stain was removed by washing with PBS 1x three times and 
cells were fixed for 10 minutes at room temperature using formalin solution (10% neutral 
buffered containing formaldehyde 4% w/v) (Sigma-Aldrich, UK). Fixed cells were 
washed twice more with PBS1x and images were taken using a Nikon DSFi1 digital 
camera coupled to a Nikon ECLIPSE TS100 microscope at 4 x magnification. Gap 
creators were removed in the remaining wells and cells incubated in HUVEC medium 
supplemented with VEGF (25 ng/ml) in the presence of DMSO or 250 nM ATA for 24 
hours (t=24). After incubation, cells were stained, fixed and images captured as above.  
HUVECs Infected with Ad-LacZ and Ad-ID4 at MOI=150 were plated at a density of 
7x105 cells/well in pre-coated 24-well cell culture cluster plates (COSTAR®, UK). 
Migration assay was performed as described above. 
Migration assay using PMCA4+/+ and PMCA4-/- MLECs were carried out using the 
protocol mentioned above except that MLEC tissue culture medium was used in the 
assay, and VEGF was used at 50 ng/ml. 
In all cases, the percentage of migration was quantified using ImageJ software (National 
Institute of Health, USA)  
3.11 Matrigel tube formation assay 
96-well tissue culture plates were pre-coated with Geltrex™ Matrix (low growth factors) 
(Invitrogen) and incubated at 37ºC for 30 minutes to allow the matrigel to solidify. 
HUVECs were detached from tissue culture flasks, and washed two times with Medium 
200 without phenol red (Cascade Biologics™, UK) to remove any traces of serum and 
growth factors present in the ECGM culture medium. Cells were re-suspended in 
Medium 200 without phenol red and plated onto geltrex at a density of 1x105 cells/well 
in Medium 200 containing 2% FBS and supplemented with growth factors (25 ng/ml 
VEGF or 50 ng/ml bFGF) in the presence of ATA or DMSO (vehicle) as a control. Plates 
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were then incubated for 16 hours at 37°C. After incubation, images were recorded using 
a Nikon DSFi1 digital camera coupled to a Nikon ECLIPSE TS100 microscope at 4x 
magnification. The percentage of tube formation was quantified by counting branching 
points from the recorded images. 
3.12 MTT Assay 
MTT assays were carried out to determine the cytotoxicity of ATA in endothelial cells. 
HUVECs were detached by trypsinisation, seeded on 96-well tissue culture plates 
(without gelatin pre-coating) at a density of 5x104 cells/well, and incubated overnight at 
37ºC. The following day one of the plates was analysed by MTT assay (t=0) by adding 
50 µl/well of a 5 mg/ml solution of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) directly to the culture medium. Plates were wrapped in aluminium 
foil to keep the reaction in the dark and incubated for 4 hours at 37°C. After incubation, 
medium containing MTT solution was removed, and 175 μl/well of DMSO and 25μl of 
Sorensen’s glycine buffer (0.1 M glycine-0.1 M NaCl equilibrated to pH10.5) were added 
to the cells. Absorbance at 540 nm was measured using a Multiskan Ascent plate 
reader (Thermo Labsystems, UK). In the remaining plates, the medium was replaced 
with HUVEC medium containing VEGF (25 ng/ml) and ATA or DMSO as required, and 
cells were further incubated at 37ºC, 5% CO2 for 3 days before MTT analysis (T=3). In 
another set of plates (T=6) the medium was changed as above, cells incubated for 3 
additional days, and viability assessed by MTT assay after the incubation period. 
For incubation of endothelial cells with ATA for long periods, HUVECs were cultured in 
T75 tissue culture flasks and incubated for 7 days with vehicle (DMSO) or ATA in the 
presence of VEGF (25 ng/ml) prior to performing the assay. 
3.13 Nitric Oxide determination 
Intracellular nitric oxide (NO) bioavailability was determined using the NO-sensitive 
fluorescence probe DAF-FM (4-Amino-5-Methylamino-2’,7’-Difluororescein Diacetate). 
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HUVECs were seeded in 12 mm Nunc bottom-glass dishes (Thermo Scientific) pre-
coated with 0.1% gelatine at a density of 5 x 105 cells/plate, and incubated at 37ºC, 5% 
CO2. The following day, cells were serum-starved by incubation in ECGM containing 
0.5% FBS for 3 hours. After serum starvation, cells were incubated with L-Arginine 
(100 µM) for 15 minutes in the same serum-free medium. DAF-FM (Molecular Probes, 
UK) was added to the medium to a final concentration of 10 µm and cells incubated for 
30 minutes. Medium containing dye was removed and replaced by basal ECGM with 
0.5% FBS, and cells further incubated for 45 minutes at 37°C. After this period, cells 
were stimulated with VEGF (25 ng/ml) in the presence of ATA (250 nM) or vehicle 
(DMSO) for 5 minutes. After treatment, the reaction was stopped by removing the 
stimulus and washing cells with PBS 1x. Cells were fixed with Formalin (Sigma) for 15 
minutes at room temperature, and then, washed three times in PBS 1X. Coverslips 
were mounted using mounting medium (Vector Laboratories, Inc). Fluorescence, as an 
indication of NO production, was detected using a ZEISS LSM 880 Confocal Laser 
Scanning Microscope.    
3.14 Flow cytometry  
Flow cytometry analysis was used to monitor the purity of endothelial cells obtained 
after MLEC isolation. Cells obtained from lungs isolated from PMCA4+/+ or PMCA4-/- 
were cultured in 6 well plates pre-coated with 0.1% gelatin for 24 hours. The following 
day, cells were trypsinised and pelleted by centrifugation at 1200 rpm for 5 minutes. The 
supernatant was removed and the cells were washed with 5 ml of sterile PBS 1x twice. 
The final cell pellet was re-suspended in 200 μl of sterile PBS. Ice-cold methanol (500 
µl) was slowly added to the cell suspension on a vortex mixer, and cells were fixed for 
15 minutes on ice. After 15 minutes, the fixed cells were pelleted by centrifugation at 
1200 rpm for 5 minutes, the methanol was removed and the cell pellet was washed with 
sterile 1x PBS. An antibody against ICAM-2 (CD102) was diluted 1:50 in FACS buffer 
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(0.1% BSA, 0.01% Triton X-100 (Sigma-Aldrich, UK), PBS) and this solution added to 
the cells for incubation at room temperature for 3 hours. After incubation, cells were 
washed with PBS1x to remove any unbound primary antibody and then incubated for 1 
hour, at room temperature in the dark, with a FITC-conjugated secondary antibody 
prepared in FACS buffer at a dilution 1:500.  After incubation, the cells were washed 
and re-suspended in FACS buffer and analysed using a Flow cytometer (BD Accuri C6). 
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Results 
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4.1 (Aim 1) To determine the activity of the calcineurin/NFAT pathway in 
endothelial cells when PMCA4 activity is inhibited by treatment with ATA. 
It has been previously reported by our group that PMCA4 negatively regulates the 
VEGF-mediated activation of the calcineurin/NFAT signal transduction pathway in 
endothelial cells (Baggott et al., 2014). Additionally, the identification of the molecule 
aurintricarboxylic acid (ATA) as a potent inhibitor of isoform PMCA4 (Mohammed et al., 
2013) encouraged us to examine whether inhibition of PMCA4 with ATA improves 
VEGF-induced calcineurin/NFAT signalling. Thus our first aim was to determine whether 
inhibition of PMCA4 by ATA will affect the activity of calcineurin/NFAT pathway in 
endothelial cells stimulated with VEGF. 
To test this possibility, HUVEC cells were infected with adenovirus Ad-NFAT-Luc (an 
NFAT-dependent, luciferase-based adenoviral reporter vector previously used by our 
group to determine the activity of the calcineurin/NFAT pathway in endothelial cells 
(Baggott et al., 2104)). This vector contains 3 copies of the NFAT-binding site of the IL-2 
promoter placed upstream of the minimal promoter region of the thymidine kinase gene. 
The artificially created promoter is located upstream of the luciferase gene, and, 
therefore, expression of luciferase in the infected cells is highly dependent on activation 
of the calcineurin/NFAT pathway. Inhibition of PMCA4 by ATA reaches saturation at low 
concentrations of ATA in the range of 250 nM (Mohammed et al., 2013). Therefore, in 
this study we decided to use this dose of ATA to achieve selective inhibition of PMCA4 
while avoiding potential deleterious side-effects of the drug on the cells. Moreover, 
maintaining ATA at low concentration also ensured that the effects observed by treating 
cells with ATA are due to inhibition of PMCA4, and no of other molecules such as 
nucleases, calpain or chemokine receptors that have been reported to be inhibited by 
ATA at the 5-20 µM high concentration range (Posner et al., 1995; Hallick et al., 1997; 
Laufenberg et al., 2014)). Infected cells were then treated with ATA (250 nM) or DMSO 
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for one hour and then stimulated with VEGF (25 ng/ml) for 6 hours after 18 hours serum 
starvation. Luciferase activity was then determined in these cells as a surrogate 
measurement of the activity of the calcineurin/NFAT pathway. As expected, stimulation 
of control cells with VEGF strongly induced the activity of the calcineurin/NFAT pathway 
(Figure 4.1). ATA treatment did not alter the activity of the calcineurin/NFAT pathway in 
control unstimulated cells, however, ATA further enhanced (78.1% increase) the strong 
activation of calcineurin/NFAT signalling induced by VEGF (Figure 4.1). This result 
supports our hypothesis that inhibition of PMCA4 function by ATA can reverse the 
negative effect exerted by the pump on calcineurin/NFAT signalling. 
 
 
 
Figure 4.1 ATA enhances the VEGF-induced activation of calcineurin/NFAT signalling in 
endothelial cells. HUVECs infected with the NFAT-dependent, luciferase reporter adenovirus 
Ad-NFAT-Luc (MOI=50) were treated with VEGF (25 ng/ml), or left untreated (control), in the 
presence of ATA (250 nM) or vehicle (DMSO). Cells were lysed 6 hours post stimulation and 
luciferase activity determined as an indication of the activity of the calcineurin/NFAT pathway. 
Results are expressed as fold-induction over the calcineurin/NFAT activity detected in control 
cells treated with DMSO. Data are plotted as mean ± SE, n=12, obtained from 3 independent 
experiments. ***denotes statistically significant differences (P≤0.005, according to one-way 
ANOVA with post hoc Tukey´s comparison test) in the VEGF-induced NFAT activity of cells 
treated with ATA vs vehicle (DMSO). 
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4.2 (Aim 2) To determine the effect of PMCA4 inhibition by ATA on the expression 
of VEGF-responsive, pro-angiogenic, NFAT-target genes.  
To investigate whether the increase in calcineurin/NFAT activity induced by ATA in cells 
stimulated with VEGF translates into an enhanced expression in VEGF-responsive, pro-
angiogenic, NFAT-target genes we decided to analyse the expression of the protein 
RCAN1.4 in HUVEC cells stimulated under these conditions.  
It has been widely demonstrated that VEGF strongly induces the expression of 
RCAN1.4 (also called DSCR-1) in a calcineurin/NFAT-dependent manner (Ryeom et al., 
2008; Holmes et al., 2010; Minami et al., 2009). The gene encoding RCAN1 is formed 
by 7 exons (Figure 4.2.1).  
                
Figure 4.2.1 Genomic structure of the human RCAN1 gene and alternative promoter 
usage (adapted from Holmes et al., 2010). Exon structure of RCAN1 gene illustrating 
alternative first exons in RCAN1.1 and RCAN1.4 isoforms. ATG indicates start codon for each 
isoform. 
 
Exons 1-4 are alternative exons. Alternative promoter usage results in two different 
RCAN1 variants. Usage of the promoter region flanking exon 1 gives rise to variant 
RCAN1.1 that contains exons 1, 5, 6, and 7 (Figure 4.2.1). Usage of the genomic region 
flanking exon 4 give rise to variant RCAN1.4 that contains exons 4, 5, 6, and 7 (Figure 
4.2.1). 15 NFAT-binding sites have been identified in the genomic region upstream of 
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exon 4 (Figure 4.2.1). Upon activation of the calcineurin/NFAT pathway by stimulation of 
endothelial cells with VEGF, occupancy of these NFAT-binding sites trigger strong up-
regulation of RCAN1.4 expression. The strong dependence of this RCAN1 variant for 
activation of calcineurin/NFAT signalling prompted us to study the expression of this 
isoform in HUVECs stimulated with VEGF in the presence or absence of ATA. 
For this purpose, HUVECs were serum-starved overnight in 0.5% fetal calf serum and 
then treated with ATA in the presence or absence of VEGF (25 ng/ml) for 4 hours. 
Protein lysates were analysed by western blot using an antibody against RCAN1.4 
(Sigma-Aldrich, UK) (see appendix 2 for table of antibodies). In agreement with the 
increased calcineurin signalling triggered by ATA in VEGF-stimulated cells (Figure 4.1) 
ATA enhanced the expression of RCAN1.4 (56.8% increment) induced by VEGF in 
HUVEC cells (Figure 4.2.2).  
 
Figure 4.2.2 PMCA4 inhibition by ATA increases the expression of VEGF responsive, pro-
angiogeneic, NFAT target protein RCAN1.4. HUVEC cells were serum-starved by overnight 
incubation in medium containing 0.5% fetal calf serum, and subsequently treated with VEGF (25 
ng/ml), or left untreated as control, in the presence of ATA (250 nM) or vehicle (DMSO). Cells 
were lysed 4 hours post stimulation. Blots show representative images of the analysis of cellular 
protein lysates by western blot to determine the levels of RCAN1.4 and tubulin (loading control) 
in the samples. Band density was analysed using ImageJ software.RCAN1.4 levels were 
normalised according to the amount of tubulin in each sample. Results in histograms show data 
as mean ± SE, n=6, obtained from 3 independent experiments. *denotes statistically significant 
differences (P≤0.05, according to unpaired, two-tailed Student t test) when comparing cells 
treated with ATA vs vehicle (DMSO).  
78 
 
Concurrently with our results in section 4.1 ATA only increased RCAN1.4 expression in 
the presence of VEGF (Figure 4.2.2). A western blot detecting tubulin (Figure 4.2.2, 
lower panel) was carried out as a loading control to confirm equal loading in all samples. 
These data indicate that ATA potentiates the VEGF-induced activation of the 
calcineurin-NFAT pathway, and that this effect is translated into enhanced expression of 
NFAT-target genes such as RCAN1.4.  
4.3 (Aim 3) To examine the effect of ATA-mediated inhibition of PMCA4 on the 
interaction between PMCA4 and calcineurin in endothelial cells. 
It is thought that PMCA4 downregulates the activity of the calcineurin/NFAT pathway via 
a molecular interaction that sequesters calcineurin into low-calcium micro-domains 
created by the calcium extrusion activity of the pump (Holton et al., 2010). Supporting 
this idea, we have demonstrated that disruption of the PMCA4/calcineurin interaction in 
endothelial cells abolishes the inhibitory effect of PMCA4 on calcineurin activity, leading 
to enhanced activation of this pathway (Baggott et al., 2014). Therefore, we next 
assessed whether the enhancement in calcineurin signalling induced by ATA is 
associated to changes in the interaction between PMCA4 and calcineurin. 
For this purpose, we used a ProteoExtract Subcellular Proteome Extraction Kit to isolate 
membrane-associated proteins from HUVECs treated with VEGF in the presence or 
absence of ATA, and analysed the contents of PMCA4 and calcineurin in this fraction. 
ATA treatment led to a significant reduction in the level of calcineurin associated to the 
plasma membrane, whereas the levels of PMCA4 remain unaffected (Figure 4.3.1A). 
Western blot analysis of the level of the plasma membrane protein cadherin was 
performed as a control to demonstrate equal amount of protein loading in all samples 
(Figure 4.3.1A).  
79 
 
                        
                       
Figure 4.3.1 ATA treatment leads to a significant reduction in the levels of calcineurin 
present in the plasma membrane of VEGF-stimulated endothelial cells. HUVEC cells 
serum-starved by overnight incubation in medium containing 0.5% fetal calf serum were treated 
with VEGF (25 ng/ml) and ATA (250 nM) or vehicle (DMSO) for 4 hours. (A) Levels of 
calcineurin and PMCA4 present in the plasma membrane were determined by western blot 
analysis of the membrane-associated protein fraction with a 1:1000 dilution of an anti-
calcineurin A antibody (α-CnA) or a 1:500 dilution of the JA3 anti-PMCA4 specific antibody (α-
PMCA4). The level of Cadherin in the samples was analysed using a monoclonal anti-cadherin 
antibody (α-Cadherin) as membrane loading control. (B) HUVEC cells treated like described 
above were lysed in Laemmli buffer to isolate total proteins. Levels of calcineurin A (α-CnA), 
PMCA4 (α-PMCA4) and Tubulin (α -Tub) were determined by western blot using antibodies 
specific for these proteins. Histogram shows levels of total calcineurin normalised to the amount 
of tubulin present in each sample. In both figures (A,B), histograms show data as mean ± SE, 
obtained from 3 independent experiments. **indicates statistically significant differences 
(P≤0.01, according to unpaired, two-tailed Student t test) in the levels of calcineurin present in 
the membrane in VEGF-stimulated cells treated with ATA vs vehicle (DMSO). ns=non-
significant. 
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To discard that reduction in membrane-associated calcineurin was attributable to 
downregulation of calcineurin expression in ATA-treated cells, we analysed the 
expression of this protein in total extracts isolated from whole cells. Total levels of 
calcineurin were equivalent in control (DMSO) or ATA-treated cells (Figure 4.3.1B). 
Likewise, analysis of total levels of PMCA4 in the same samples did not show any 
significant differences (Figure 4.3.1B). Equal protein loading in the sample was 
confirmed by western blot analysis of tubulin contents in the extracts of total protein 
used in the experiment (Figure 4.3.1B). These results suggest that treatment of 
HUVECs with ATA releases calcineurin from its interaction with PMCA4 in the plasma 
membrane.    
To confirm that the decrease in the level of calcineurin associated to the membrane was 
the result of disruption of the PMCA4/calcineurin interaction, we performed 
immunoprecipitation experiments. Total protein extracts isolated from HUVECs 
stimulated with VEGF in the presence or absence of 250 nM ATA were 
immunoprecipitated with an anti-calcineurin antibody. Western blot of the 
immunoprecipitated proteins revealed that treatment with ATA significantly reduced the 
amount of PMCA4 co-precipitated with calcineurin, indicating dissociation of the 
PMCA4/calcineurin complex (Figure 4.3.2). Similar levels of calcineurin were 
precipitated in the presence or absence of ATA (Figure 4.3.2), ruling out the possibility 
that changes in the affinity for calcineurin of the immunoprecipitating antibody in ATA 
treated cells were the reason for the decrease in PMCA4 co-precipitation. 
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Figure 4.3.2 PMCA4 inhibition by ATA releases calcineurin from its interaction with 
PMCA4. HUVECs treated with VEGF (25 ng/ml) and ATA (250 nM) or vehicle (DMSO) for 4 
hours, were lysed and total proteins immunoprecipitated with an anti-calcineurin antibody. 
Levels of calcineurin and PMCA4 in the precipitated proteins were determined by western blot 
(α-CnA and α-PMCA4, respectively). Histogram shows levels of co-precipitated PMCA4 
normalised to the amount of calcineurin precipitated in each assay. Histogram represents mean 
± SE, obtained from 3 independent experiments. *denotes statistically significant differences 
(P≤0.05, according to unpaired, two-tailed Student t test) in the amount of PMCA4 co-
precipitated with calcineurin in VEGF-stimulated HUVECs treated with ATA vs vehicle (DMSO).  
 
Altogether, the data presented in these sections suggest that ATA-treatment results in 
disruption of the PMCA4/calcineurin interaction. The release of calcineurin from the 
inhibitory effect exerted by PMCA4 would result in an enhancement of the VEGF-
induced activation of the calcineurin/NFAT pathway that would lead to up-regulation in 
the expression of the endothelial NFAT-target gene RCAN1.4. 
4.4 (Aim 4) To investigate the effect of PMCA4 inhibition by ATA on endothelial 
cell motility. 
4.4.1 Effect of ATA on the motility of HUVEC cells 
We have previously reported that PMCA4 downregulates endothelial cell migration and 
tubular morphogenesis via the establishment of an inhibitory molecular interaction with 
cytoplasmic calcineurin (Baggott et al., 2014). The strong enhancement on the activity 
of the calcineurin/NFAT pathway induced by ATA in VEGF-stimulated HUVECs (Figure 
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4.1) prompted us to postulate that ATA should reverse the negative effect exerted by 
PMCA4 on these angiogenic processes. To investigate this possibility, HUVEC cells 
were plated in pre-coated 24-well cell culture plates and a 0.9 mm gap was created 
using a ‘’gap generator’’ from a wound healing assay kit (Cell Biolabs Inc). Cells were 
stained and fixed at time zero and after 24 hours of incubation with VEGF in the 
presence of absence of ATA. Images were taken at time zero and after 24 hours, and 
closure of the gap (indicating cellular migration) was analysed using ImageJ software. 
Endothelial cell migration was found to increase significantly (58.4 % increment) by ATA 
treatment compared to the migration of control cells treated with DMSO (Figure 4.4.1) 
highlighting that ATA increases HUVEC cell motility in response to VEGF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.1 ATA treatment increases cell migration of HUVEC cells stimulated with 
VEGF. HUVEC cells plated on 24-well tissue culture plates to carry out wound healing migration 
assays, were fixed at time zero or after incubation in ECGM supplemented with VEGF (25 
ng/ml) in the presence of ATA (250 nM) or DMSO for 24 hours. Images were taken using a 
Nikon DSFi1 digital camera coupled to a Nikon ECLIPSE TS100 microscope at 4x magnification 
and wound closure analysed with ImageJ software. VEGF-stimulated endothelial cell migration 
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was significantly increased by ATA treatment. Representative images of endothelial wound-
healing migration assays are shown. Cell migration was determined by subtracting the value of 
the non-migrated area from the initial wound area (time=0), and expressing this value as a 
percentage of the total area at time zero. Histogram shows data as mean ± SE, n=9, obtained 
from 3 independent experiments. ***denotes statistically significant differences (P≤0.005, 
according to unpaired, two-tailed, Student t test) in the migration of cells treated with ATA vs 
vehicle (DMSO).  
 
4.4.2 Analysis of involvement of PMCA4 on the ATA-mediated enhancement of 
endothelial cell motility 
To determine that the improving effect of ATA on endothelial cell motility involves 
inhibition of PMCA4, and is not the consequence of an off-target effect in the cell, we 
performed migration assays using mouse lung endothelial cells (MLECs) isolated from 
PMCA4-/- knockout mice or their wild-type littermates.  
To verify that our procedure for isolation of MLEC cells from mouse lungs yielded a 
population of endothelial cells without significant contamination by other pulmonary cell 
types, we analysed the percentage of cells in the isolated population expressing the 
endothelial cell marker ICAM-2 (CD102). Both PMCA4+/+ and PMCA4-/- cells were 
used for  flow cytometry analysis and showed that around 90% of the cells expressed 
ICAM-2 in the cell surface (Figure 4.4.2.1), confirming the enrichment of endothelial 
cells in the population after the isolation/purification procedure. No difference in the yield 
of isolated MLEC cells was observed when isolation was performed with lungs coming 
from PMCA4+/+ and PMCA4-/- mice. 
 
 
84 
 
 
 
Figure 4.4.2.1 Flow cytometric analysis of endothelial cell marker (CD102) expression on 
MLEC cells. MLEC cells isolated from PMCA4+/+ or PMCA4-/- mice were cultured in 6- well 
plates pre-coated with 0.1% gelatine for 24 hours. Expression of endothelial surface marker 
CD102 was measured by using flow cytometry analysis. A) Control flow cytometry analysis 
performed incubating the cell population only with anti-IgG FITC-conjugated secondary 
antibody. Most of the cells appear as CD102(-). (B) Flow cytometry analysis performed 
incubating the cells with primary anti-CD102 antibody and then with anti-IgG FITC-conjugated 
secondary antibody. 92.9% of the cells were detected as CD102(+). (C) Overlapping 
representation of CD102(+) cells in experiments (A) and (B). Fluorescence of control cells 
incubated only with anti-IgG(FITC) is shown in red. Fluorescence of cells incubated with anti-
CD102 and anti-IgG(FITC) is shown in green. Images are shown above is from PMCA4+/+ 
cells. Images are representative of three independent experiments. Histogram shows % of 
CD102(+) cells in flow cytometry analysis when the isolated cell population was stained as 
described in A (PBS+FITC, control) or in B (CD102+FITC). Data are shown as mean ± SE, n=7, 
obtained from 3 independent experiments of MLEC isolation/purification.   
 
 
To demonstrate the successful knockout of PMCA4 in the isolated MLEC cells, we 
collected RNA and protein samples from cells isolated from PMCA4+/+ or PMCA4-/- mice 
and analysed the expression of the PMCA4 gene in these cells by qPCR and western 
2.0% 92.9% 
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blot, respectively. PMCA4 RNA and protein were clearly present in wild-type cells but 
neither were detected in cells obtained from knockout animals (Figure 4.4.2.2). 
 
 
Figure 4.4.2.2 Successful isolation of PMCA4+/+ or PMCA4-/- MLEC. A) MLEC cells isolated 
from PMCA4+/+ or PMCA4-/- mice were cultured in 6 well plates for 24 hours. Protein samples 
were analysed by western blot using anti-PMCA4 (JA9) monoclonal antibody. Expression levels 
of Tubulin (α-Tub) were used as loading control. B) RNA was extracted from PMCA4+/+ or 
PMCA4-/- MLEC cells and reverse transcribed into cDNA. PMCA4 mRNA expression was 
determined by qRT-PCR using TaqMan Gene Expression Assays. Absence of PMCA4 RNA 
amplification (left panel) in qPCR reactions carried out with samples reverse-transcribed with 
RNA isolated from PMCA4-/- MLEC confirmed loss of PMCA4 expression in these cells. GAPDH 
amplification (right panel) confirmed equal amount of cDNA in samples originated from wild-type 
or PMCA4 knockout MLEC cells.  
 
Isolated PMCA4+/+ and PMCA4-/- MLEC cells were plated as described in section 4.4.1 
and migration was analysed after 24 hours of stimulation with VEGF (50 ng/ml). 
Consistent with our published observations (Baggott et al., 2014) PMCA4-deficient cells 
migrated longer than their corresponding wild-type counterparts (Figure 4.4.2.3). 
However, whereas ATA improved (64.9% increment) the ability of wild-type MLECs to 
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migrate, it did not have any effect at all on the migration of PMCA4-defficient cells 
(Figure 4.4.2.3). These results imply PMCA4 in the enhancement of endothelial cell 
motility triggered by ATA.  
 
 
4.4.2.3 PMCA4 inhibition by ATA enhances MLEC motility in PMCA4+/+ (wildtype) but not 
in PMCA4-/- (knockout) cells. Migration of MLEC cells was analysed at time zero or after 
incubation in MLEC medium supplemented with VEGF (50 ng/ml) in the presence of ATA (250 
nM) or DMSO for 24 hours. Images are representative of wound healing migration assays at 0 
and 24 hours. Cell migration was determined by subtracting the values of the non-migrated area 
from the initial wound area (time 0), and expressing this value as a percentage of the total area 
at time zero. Histogram shows data as mean ± SE, n=6, obtain from 3 independent 
experiments. Differences were analysed for statistical significance by one-way ANOVA with post 
hoc Tukey´s comparison test. ***indicates statistically significant differences (P≤0.005) in the 
migration of PMCA4+/+ MLECs treated with ATA vs vehicle (DMSO). ####denotes statistically 
significant differences (P≤0.001) in the motility of wild-type (+/+) vs PMCA4 knockout (-/-) 
MLECs. ns=non-significant. 
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In this study, we show that treatment with ATA impairs the molecular association 
between PMCA4 and calcineurin in endothelial cells (Figure 4.3.1 and 4.3.2). To 
investigate whether the ATA-mediated enhancement in endothelial cell motility involves 
disruption of the PMCA4/calcineurin interaction, we carried out cell migration assays 
using HUVECs where the PMCA4/calcineurin interaction was already disrupted by 
overexpression of the interaction domain of PMCA4 that interacts with calcineurin. We 
have previously reported that ectopic expression of the region 428-651 of PMCA4b, that 
corresponds to the domain of PMCA4 implicated in the interaction with calcineurin 
(Buch et al., 2005), disrupts the PMCA4/calcineurin interaction in endothelial cells 
(Baggott et al., 2014). Therefore, we infected HUVEC cells with Ad-ID4, an adenovirus 
encoding a Flag-tagged version of the fragment encompassing aminoacids 428 to 651 
of human PMCA4 (from now on this domain of PMCA4 will be reffered to as ID4), and 
carried out migration assays in the infected cells. As a control, HUVECs were infected 
with an adenovirus encoding β-Galactosidase (Ad-LacZ). In agreement with our results 
presented in Figure 4.4.1 ATA boosted (64.9% increment) the migration of control cells 
infected with Ad-LacZ (Figure 4.4.2.4). Disruption of the PMCA4/calcineurin interaction 
in HUVECs infected with Ad-ID4 led to an increase in the migration of the cells as we 
have previously reported (Baggott et al., 2014), but, conversely to our result in control 
cells, treatment with ATA did not further improve the migration of these cells (Figure 
4.4.2.4). Equal expression of the PMCA4-interaction domain (ID4) in cells treated with 
DMSO or ATA confirmed that ATA treatment did not alter the infection efficiency of the 
Ad-ID4 adenovirus (Figure 4.4.2.5).  These data, not only reassure the implication of 
PMCA4 on the enhancement of endothelial cell migration triggered by ATA, but also 
reveal that disruption of the interaction between PMCA4 and calcineurin is a key 
molecular mediator of this process. 
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Figure 4.4.2.4 ATA increases endothelial cell motility via disruption of the 
PMCA4/calcineurin interaction. HUVEC cells were infected with Ad-LacZ or Ad-ID4 and 
plated in pre-coated 24-well tissue culture plates using a 0.9 mm gap generator from a wound 
healing assay kit to create a 0.9mm gap. Images, taken at time zero and after incubation for 24 
hours are representative of 3 independent experiments. Cell migration was determined by 
subtracting the value of the non-migrated area from the initial wound area (time=0), and 
expressing this value as a percentage of the total area at time zero. Data are plotted as mean ± 
SE, n=3, obtained from 3 independent experiments. Differences were analysed for statistical 
significance by one-way ANOVA with post hoc Tukey´s comparison test. *indicates statistically 
significant differences (P≤0.05) in the motility of Ad-LacZ-infected cells treated with ATA vs 
vehicle (DMSO). ###denotes statistically significant differences (P≤0.005) in the migration of cells 
infected with Ad-LacZ vs Ad-ID4. ns=non-significant.  
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Figure 4.4.2.5 ATA does not alter the adenovirus-mediated expression of Flag-ID4. 
HUVECs infected (MOI=150) with Ad-LacZ (encoding β-Galactosidase) or Ad-ID4 (encoding a 
Flag-tagged version of the domain of PMCA4 implicated in the interaction with calcineurin) were 
incubated in medium containing VEGF (25 ng/ml) in the presence of ATA (250 nM) or vehicle 
(DMSO). Samples were analysed by western blot using anti-Flag M2 monoclonal antibody. 
Expression levels of Tubulin (α-Tub) were determined as loading control. Histogram shows data 
as mean ± SE, n=3, obtained from 3 independent experiments. Results were analysed for 
statistically significant differences by unpaired, two-tailed Student t test. ns=non-significant. 
 
4.5 (Aim 5) To determine the effect of ATA-mediated inhibition of PMCA4 on 
endothelial cell tubular morphogenesis. 
It is well established that both, PMCA4 and the calcineurin/NFAT pathway actively 
participate in the regulation of blood vessel formation (Baggott et al., 2014; Hernandez 
et al., 2001). Thus, we next studied the effect of ATA on endothelial cell tubular 
morphogenesis. In agreement with previous reports, treatment with VEGF increased the 
ability of endothelial cells to form tubular-like structures in Matrigel assays (Figure 4.5A). 
ATA on its own did not have any effect on endothelial cell tubular morphogenesis 
(Figure 4.5A). However, VEGF-ATA cotreatment further enhanced the VEGF-mediated 
increase in tube formation (38.9% increment with respect to control cells) (Figure 
4.5.1A). ATA did not increase tubular morphogenesis in cells stimulated with basic 
Fibroblast Growth Factor (bFGF) (Figure 4.5B), a pro-angiogenic factor that does not 
activate the calcineurin/NFAT pathway (Hernandez et al., 2001), denoting a critical role 
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of the calcineurin/NFAT pathway in the enhancement of tubular morphogenesis induced 
by ATA.  
 
 
Figure 4.5 ATA enhances endothelial cell tubular morphogenesis in response to VEGF 
but not FGF stimulation. HUVECs plated on a layer of Growth-Factor Reduced Matrix 
(Geltrex) in Medium 200 containing 2% fetal bovine serum were treated when indicated with 
VEGF (25 ng/ml) (A) or bFGF (50 ng/ml) (B) in the presence of ATA (250 nM) or vehicle 
(DMSO). Representative images are shown. Histograms show data as mean ± SE, n=6 in (A) 
and n=4 in (B), obtained from 3 (A) and 2 independent experiments (B) respectively. Data were 
analysed for statistically significant differences by one-way ANOVA with post hoc Tukey’s 
comparison test. ***indicates statistically significant differences (P≤0.005) when comparing tube 
formation in VEGF-stimulated cells treated with ATA vs vehicle (DMSO). ns=non-significant.     
 
To substantiate the significance of the enhancement in blood vessel formation induced 
by ATA-mediated inhibition of PMCA4, our collaborators Dr Dolores Lopez-Maderuelo 
and Professor Juan Miguel Redondo (Centro de Investigaciones Cardiovasculares, 
CNIC, Madrid, Spain) have evaluated the effect of ATA in vivo in the mouse hindlimb 
ischaemia model. ATA (or DMSO as control) was administered intraperitoneally to mice 
undergoing experimentally-induced unilateral ischaemia by femoral artery ligation in the 
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lower limb. Laser Doppler analysis of blood flow revealed a robust increment in the 
reperfusion of post-ischaemic limbs treated with ATA. These results, shown in appendix 
3 (Figure Appendix 3A) with the permission of Dr Dolores Lopez-Maderuelo and 
Professor Juan Miguel Redondo, not only confirm our observation but also highlight the 
potential of targeting endothelial PMCA4 with therapeutic purposes to treat patients 
suffering from cardiovascular ischaemic disease. 
4.6 (Aim 6) To examine the effect of ATA on the viability of endothelial cells. 
Our observations suggest that ATA might be used with therapeutic purposes to promote 
blood vessel formation in pathological settings occurring with insufficient angiogenesis. 
As a first step to evaluate this possibility we examined whether ATA has any toxic effect 
on the viability of endothelial cells. For this purpose, we cultured HUVECs for 3 and 6 
days in the presence of 250 nM ATA or vehicle (DMSO) and determined the viability of 
the cells performing MTT assays. At low concentrations (250 nM) ATA did not alter the 
proliferation/viability of the cells (Figure 4.6.1A).  
 
Figure 4.6.1 ATA is not toxic to endothelial cells at low concentration. HUVECs were 
plated on 96-well plates and cell viability determined by MTT assay after overnight incubation 
(t=0) and after incubation for 3 and 6 days in culture medium supplemented with VEGF (25 
ng/ml) in the presence of ATA (250 nM) or vehicle (DMSO). Histogram shows data as mean ± 
SE, n=3, obtained from 3 independent experiments. (B) Western blot analysis of the 
phosphorylation (activation) status of Erk1-2 proteins using an anti-Phospho-specific-Erk1-2 
antibody in HUVECs stimulated when indicated with VEGF for 5 minutes in the presence of ATA 
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(250 nM) or vehicle (DMSO). Histogram represents data as mean ±SE, n=5, obtained from 3 
independent experiments. Phosphorylation levels of Erk1-2 were normalized to the amount of 
total Erk1-2 present in each sample. Data are expressed as fold-induction in Erk1-2 
phosphorylation respect to that found in unstimulated cells. ns=non-significant. 
 
In concurrence with these results, treatment with 250 nM ATA did not affect the VEGF-
induced phosphorylation (activation) status of Erk1/2 proteins in endothelial cells (Figure 
4.6.1B), indicating that low concentrations of ATA do not modify the activity of this 
proliferative signal transduction pathway.  
Increasing the concentration of ATA to 20 µM had, however, a negative effect on cell 
viability when HUVECs were exposed to the drug for 2 weeks (Figure 4.6.2A). 
 
Figure 4.6.2 HUVECs exposure to high ATA levels impairs cell viability and tube 
formation. (A) HUVECs were incubated in endothelial cell medium containing 20 μM ATA or 
vehicle (DMSO) for 1 week, changing medium every 2-3 days. Subsequently, cells were seeded 
on 96-well plates and viability determined by MTT the day after plating cells (t=0) and after 
incubation for 3 and 6 days in medium supplemented with VEGF (25 ng/ml), and 20 μM ATA or 
vehicle (DMSO). Histogram shows data as mean ± SE, n=4, obtained from 4 independent 
experiments. Data were analysed for statistically significant differences by one-way ANOVA with 
post hoc Tukey’s comparison test. ****indicates statistically significant differences (P≤0.001) 
when comparing cells incubated in the presence of 20 μM ATA vs vehicle (DMSO). ns=non-
significant. (B) HUVECs were incubated in medium containing 0.25 μM ATA, 20 μM ATA or 
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vehicle (DMSO) for 1 week, changing medium every 2-3 days. Subsequently, cells were seeded 
on a layer of Growth-Factor Reduced Matrix (Geltrex) in Medium 200 containing 2% fetal calf 
serum, VEGF (25 ng/ml) and 0.25 μM ATA, 20 μM ATA or vehicle (DMSO) and incubated for 24 
hours longer. Images are representative of two independent experiments. 
 
Likewise, high levels of ATA (20 µM) completely abolished the ability of VEGF-
stimulated HUVECs to form capillary-like structures in matrigel assays (Figure 4.6.2B). 
In agreement with the harmful effects exerted by high concentration of ATA observed in 
our in vitro assays using endothelial cells (Figure 4.6.2), our collaborators Mr Aaron 
Savage and Dr Robert Wilkinson (Department of Infection, Immunity and 
Cardiovascular Disease and Bateson Centre, University of Sheffield, UK) have found 
that treating zebrafish embryos with ATA at low concentration caused no significant 
damage to the embryos which develop a normal vascular anatomy. However, 
increasing the concentration of ATA above 100 µM caused embryo death. These 
results, shown in appendix 3 (Figure Appendix 3B) with the permission of Mr Aaron 
Savage and Dr Robert Wilkinson confirm in a more physiological setting the in vitro data 
obtained in primary endothelial cells. 
4.7 (Aim 7) To determine the effect of ATA on the interaction of PMCA4 with 
endothelial nitric oxide synthase (eNOS). 
Here, we demonstrate that the calcineurin/NFAT signalling pathway has a key role in 
the enhancement of VEGF-induced angiogenesis promoted by inhibition of PMCA4 with 
low concentrations of ATA, however, our results do not rule out the potential 
participation of other signalling pathways. In addition to calcineurin, we have recently 
shown that PMCA4 also downregulates the activity of eNOS, and the subsequent 
production of nitric oxide (NO) in endothelial cells (Holton et al., 2010). The pro-
angiogenic properties of NO are well established, and eNOS activation and NO 
production is induced by endothelial cell stimulation with VEGF. Thus, it is tempting to 
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speculate that NO-dependent signalling pathways might also be implicated in the 
angiogenic enhancement exerted by ATA in VEGF-stimulated endothelial cells. To 
investigate this possibility, we first determined whether exposure of endothelial cells to 
ATA leads to disruption of the PMCA4/eNOS interaction in a similar manner to the effect 
observed for the PMCA4/calcineurin interaction. However, when we immunoprecipitated 
PMCA proteins from lysates of HUVECs treated with VEGF and ATA (or DMSO as 
control) and analysed the levels of co-precipitated eNOS, we observed that ATA led to 
an increment in the level of eNOS associated to PMCA4 (Figure 4.7A). As we have 
previously reported that the interaction between PMCA4 and eNOS results in 
downregulation of eNOS activity (Holton et al., 2010), we next studied the functional 
effect of ATA on the synthesis of nitric oxide (NO) by endothelial cells stimulated with 
VEGF. As we could anticipate, ATA treatment significantly diminished the synthesis of 
NO in HUVECs stimulated with VEGF (Figure 4.7B). The reduction in NO synthesis 
promoted by ATA is likely to be the result of enhancement of the PMCA4/eNOS 
interaction. 
Altogether, these results seem to exclude NO as one of the effectors implicated in the 
boost of VEGF-induced angiogenesis promoted by inhibition of PMCA4 with ATA. 
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Figure 4.7 ATA treatment potentiates the PMCA4/eNOS interaction and attenuates nitric 
oxide synthesis in endothelial cells stimulated with VEGF. (A) Serum-starved HUVECs 
were treated with VEGF (25 ng/ml) and ATA (250 nM) or vehicle (DMSO) for 5 minutes. Protein 
lysates were immunoprecipitated with the anti-PMCA 5F10 monoclonal antibody, and levels of 
PMCA4 and eNOS in the immunoprecipitated proteins analysed by western blot. Histogram 
shows levels of co-precipitated eNOS normalised to the amount of PMCA4 precipitated in each 
assay. Data are shown as mean ± SE obtained from 3 independent experiments. **indicates 
statistically significant differences (P≤0.01, according to unpaired, two-tailed Student t test) in 
the levels of eNOS co-precipitated in samples treated with ATA vs vehicle (DMSO). Western 
blot images are representative of 3 independent immunoprecipitation experiments. (B) HUVECs 
were treated as indicated in (A). Intracellular levels of nitric oxide were determined by staining 
cells with the NO sensitive dye DAF-FM. Images showing microscopy fields of DAF-FM staining 
in cells are representative of 2 independent experiments performed in duplicate. 
 
A 
B 
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CHAPTER 5 
Discussion and Future work 
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5.1 Discussion  
Ischaemic cardiovascular diseases such as ischaemic heart disease, peripheral arterial 
disease, and stroke, constitute a leading primary cause of morbidity and mortality 
worldwide (Mozaffarian et al., 2015). During the last decades, the treatment for 
ischaemic cardiovascular disease has advanced into an inspiring new era. Bypass 
surgery and interventional endovascular procedures are currently applied to patients 
with ischaemic cardiovascular disease to successfully restore the flow of blood in the 
ischaemic tissues (Al Sabti, 2007; Sachs et al., 2011). However, in many cases, the 
extensive distribution and diffuseness of arterial occlusions makes a high proportion of 
patients unsuitable for surgical revascularisation (Sachs et al., 2011). Therapeutic 
interventions aimed to induce the formation of new blood vessels in the ischaemic 
organs (referred to as therapeutic angiogenesis) represent a very promising alternative 
to treat these patients. 
Given the relevance of the pro-angiogenic factor VEGF as a pivotal mediator of blood 
vessel formation (that we have described in detail in the introduction section of this 
thesis), it is not surprising that a number of gene-based and protein-based therapeutic 
approaches have been developed in the last 10 years to deliver exogenous VEGF to 
ischaemic tissues (Zachary and Morgan, 2011). An impressive body of data obtained 
from preclinical studies carried out in animal models of myocardial and limb ischaemic 
disease showed that ectopic delivery of VEGF led to successful reperfusion of the 
ischaemic organ (Ylä-Herttuala, 2013; Zachary and Morgan, 2011). Unfortunately, 
translation of these procedures onto treatment of human cardiovascular ischaemic 
diseases have only shown limited benefits for patients thus far (Gupta et al., 2009). The 
reasons behind lack of success in trials of treatments based on therapeutic 
angiogenesis are complex, but one major problem in current interventions is failure to 
reinstate efficient VEGF activity in the ischaemic human tissue (Ylä-Herttuala, 2013; 
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Zachary and Morgan, 2011; Gupta et al., 2009). Therefore, there is an urgent need to 
develop new therapeutic approaches that improve VEGF-based blood vessel formation 
in patients with occluded arteries. A full understanding of the molecular mechanisms 
that regulate reparative angiogenesis and collateral development in ischaemic tissues is 
an essential requirement for the design of novel, more efficient therapeutic interventions 
that promote reparative revascularization. The work presented in this thesis has 
established proof-of-concept for the potential of targeting endothelial PMCA4 to promote 
blood vessel formation with therapeutic purposes. Pharmacological suppression of 
PMCA4 function seems a feasible strategy for therapeutic interventions in clinic, as 
PMCA4 deficiency in mouse knockout models does not cause any pathological 
phenotype in the animal apart from male infertility (Such et al., 2005).  
In this work we demonstrate that inhibition of PMCA4 function with low concentrations of 
the small polyaromatic compound aurintricarboxylic acid (ATA) increases VEGF-
mediated angiogenesis in vitro. Consistently with our in vitro data obtained using 
cultured primary human endothelial cells, our collaborators Dr Dolores Lopez-
Maderuelo and Professor Juan Miguel Redondo (Centro de Investigaciones 
Cardiovasculares, CNIC, Madrid, Spain) have evaluated in pre-clinical animal models 
the potential of using ATA to promote blood vessel formation in ischaemic organs. Their 
results, presented in appendix 3A (with permission of Dr Lopez-Maderuelo and 
Professor Juan Miguel Redondo) show that administration of ATA significantly 
enhances the reperfusion of ischaemic limbs in a murine animal model of experimental 
hind limb ischaemia (Figure Appendix 3A, appendix 3) indicating the potential 
application of ATA in pro-angiogenic therapies. The feasibility of ATA in clinic has yet to 
be tested but pre-clinical studies using animal models have revealed potential clinical 
applications for ATA in the treatment of cardiac hypertrophy (Mohamed et al., 2016), 
experimental autoimmune encephalomyelitis (Zhang et al., 2013), sepsis (Laufenberg et 
99 
 
al., 2014), or myocardial ischaemia-reperfusion injury (Zhao et al., 2003). However, the 
results from this thesis anticipate some problems (dosage and duration of treatment) for 
the clinical use of ATA in its present formulation. Our data demonstrate that potential 
therapeutic strategies based on ATA administration should take into account the 
harmful effects of the drug observed at high doses and in prolonged treatments. We 
show that high concentration of ATA (20 µM) has a negative effect on endothelial cell 
viability and completely abolishes VEGF-stimulated tube formation when HUVECs are 
exposed to the drug for two weeks. Consistent with this finding, previous studies by 
other groups have shown that increasing the concentration of ATA diminishes the ability 
of endothelial cells to form tubular-like structures in matrigel assays (Lipo et al., 2013). 
In the same work, the authors also demonstrated that injection of 1.5µg of ATA in 2µl of 
10% DMSO (that corresponds to a concentration 1.78 mM) by intravitreal injection into a 
mice model of age-related macular degeration (AMD), strongly attenuates laser-induced 
choroidal neovascularization. It is likely that the reduction in ocular vascularization 
observed in the work by Lipo et al, is due to the toxic effect exerted by high 
concentrations of ATA on endothelial cells. Supporting this possibility, experiments in 
zebrafish embryos performed by our collaborators Mr Aaron Savage and Dr Robert 
Wilkinson (University of Sheffield) (Figure Appendix 3B, appendix 3) and those 
performed by Smee et al in mice (Smee et al., 2010), clearly demonstrate the harmful 
effects exerted by high concentrations of ATA. Furthermore, other studies have shown 
that high concentrations of ATA (5-20 µM) act as an inhibiting agent for the growth of 
fibroblasts (Benezra et al., 1992) and smooth muscle cells (Benezra et al., 1994). At 
high concentrations, ATA has been reported to inhibit non-specifically the action of 
nucleases (Hallick et al., 1997), the enzyme calpain (Posner et al., 1995), several 
chemokine receptors (Zhang et al., 2013), and other molecules, offering a plausible 
explanation for the toxic effect associated to high concentrations of ATA. For this 
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reason, in this study we used a very low dose of ATA (250 nM) to ensure that its 
effects are only due to PMCA4 inhibition, and to avoid the toxicity associated to 
higher concentrations. 
Although the associated toxicity of ATA can preclude its clinical value at present, we 
have found in this work that ATA-mediated inhibition of PMCA4 can successfully 
enhance angiogenic processes, and, therefore, refined, more specific versions of 
ATA free of toxic effects might be used in the future to improve pro-angiogenic 
treatments for patients. This possibility requires further investigation. 
Our results suggest that ATA increases calcineurin-dependent angiogenic processes 
through the disruption of the interaction between PMCA4 and calcineurin at the plasma 
membrane. The molecular mechanism by which ATA promotes disruption of the 
PMCA4/calcineurin complex is not known yet. A possible explanation is that when ATA 
binds to PMCA4 to inhibit its calcium extrusion activity, it also masks the area of PMCA4 
involved in the interaction with calcineurin (amino acids 428 to 651 of human PMCA4b) 
(Buch et al., 2005). Supporting this possibility, Shadrick et al demonstrated that ATA 
inhibits the action of the hepatitis C virus helicase by masking the interaction domain 
between the enzyme and nucleic acids (Shadrick et al., 2013). However, we have also 
investigated the effect of ATA on PMCA4 binding to the endothelial nitric oxide synthase 
(eNOS), another partner protein that interacts with the same domain of PMCA4 as 
calcineurin (Holton et al, 2010; Buch et al., 2005), and we have found that rather than 
decreasing the interaction, ATA enhances the association between PMCA4 and eNOS 
(Figure 4.7.1). As ATA has opposite effects on the binding of PMCA4 with calcineurin or 
eNOS, it is unlikely to be an allosteric competitor with calcineurin or eNOS for binding to 
the domain 428 to 651 of PMCA4. Further research is necessary to fully define the 
molecular events through which ATA disrupts the PMCA4/calcineurin interaction, and 
the differential effect exerted by ATA on PMCA4 binding to calcineurin or eNOS. 
101 
 
The results presented on this thesis highlight the relevance of PMCA4 over other PMCA 
isoforms on the regulation of endothelial cell angiogenesis. As reviewed by Strehler and 
Zacharias (2001), there are four isoforms of PMCA (PMCA1-4) encoded by four 
different genes. PMCA1 and 4 are found throughout most tissues (Strehler and 
Zacharias, 2001). This work and a previous report by Holton et al., 2010 has shown the 
expression of PMCA1 and 4 in HUVEC and Human Dermal Microvascular Endothelial 
Cells (HDMEC). The expression of these proteins in other vascular beds like for 
example in aortic endothelial cells, pulmonary artery endothelial cells, coronary artery 
endothelial cells, etc has not been investigated so far. ATA has been shown to inhibit 
PMCA4 with no significant effect on PMCA1 (Mohamed et al., 2013). Therefore, 
although PMCA4 will be inhibited in cells treated with ATA, PMCA1 will still be fully 
functional in these cells. Our results indicate that ATA-mediated inhibition of PMCA4 is 
enough to enhance calcineurin-dependent blood vessel formation even in the presence 
of functional PMCA1. Although it had been traditionally considered that all PMCA 
isoforms exert a similar function as membrane extruders of cytoplasmic calcium, 
emerging evidence suggests that specific isoforms fulfil more specialised roles 
(Strehler, 2015; Little et al., 2016), and our observations are in line with this idea. 
Here, we show that treatment of endothelial cells with nanomolar concentrations of ATA 
notably enhances calcineurin/NFAT signalling pathway, and subsequently promotes 
VEGF-mediated angiogenesis. However, this finding does not rule out the activation by 
ATA of other signalling pathways involved in VEGF-mediated angiogenesis. In addition 
to calcineurin, we have recently reported that PMCA4 also downregulates the activity of 
eNOS and the subsequent production of nitric oxide (NO) in endothelial cells (Holton et 
al 2010). NO has been identified as a positive inducer of angiogenesis (Luque 
Contreras et al., 2006). Furthermore, activation and NO production are stimulated by 
treatment of endothelial cells with VEGF (Ziche and Morbidelli, 2000). Therefore, NO-
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dependent signalling pathways might also be implicated in the angiogenic enhancement 
exerted by ATA in VEGF-stimulated endothelial cells. However, we noted in this study 
that targeting PMCA4 with ATA increases the interaction between PMCA4 and eNOS in 
the presence of VEGF (Figure 4.7.1A), and, given the negative effect exerted by 
PMCA4 on eNOS (Holton et al 2010), this should lead to downregulation of eNOS 
activity. In agreement with this idea our functional experiments show that nanomolar 
concentrations of ATA significantly attenuate NO synthesis in endothelial cells 
stimulated with VEGF (Figure 4.7.1B), discarding NO as one of the effectors implicated 
in the boost of angiogenesis exerted by ATA. Still, we cannot rule out that interaction of 
PMCA4 with other signalling partner protein yet to be identified, is implicated in the 
regulation of VEGF-driven angiogenesis, and, thus, participates in the angiogenic 
enhancement induced by ATA. 
5.2 Future work 
In this study we have identified that inhibition of PMCA4 in endothelial cells by treatment 
with the PMCA-specific inhibitor ATA significantly increases the activity of 
calcineurin/NFAT pathway, endothelial motility, and blood vessel formation in response 
to VEGF stimulation. We have seen that disruption of the PMCA4/calcineurin interaction 
is essential for the ATA-induced enhancement of angiogenic processes, as endothelial 
cells where the PMCA4/calcineurin interaction is already disrupted by overexpression of 
the domain 428-651 of PMCA4 did not respond to ATA treatment. This result suggests 
that molecular strategies that disrupt the PMCA4/calcineurin interaction in endothelial 
cells might be used with therapeutic purposes to enhance VEGF-triggered angiogenesis 
in patients.  
As a first step in this direction, it would be very beneficial to characterise the molecular 
nature of the interaction between PMCA4 and calcineurin. Previous work by our 
laboratory has shown the interaction between PMCA4 and calcineurin in HEK293 and 
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endothelial cells (Buch et al., 2005; Holton et al., 2010; Baggott et al., 2014), but these 
studies have not revealed whether the interaction between the two proteins is direct or it 
involves the participation of an adaptor protein that brings them together. It would be 
interesting to use recombinant versions of PMCA4 and calcineurin to perform in vitro 
pull-down assays in the presence of the two recombinant proteins. Furthermore, these 
pull-down assays could test the relevance of other co-factors such as calmodulin, 
calcium, etc that can be easily modified in these assays by changing the conditions of 
the reaction buffer.  
Another interesting point to consider is that in this and in previous works by our 
loboratory (Buch et al., 2005; Baggott et al., 2014), we have used a large polypeptide of 
222 amino acids that corresponds to the region 428 to 651 of PMCA4. Although this 
polypeptide has proven extremely useful to establish proof-of-concept on the potential 
of disrupting the PMCA4/calcineurin interaction in endothelial cells to boost VEGF-
driven angiogenesis, clinical delivery of such a big protein in patients might turn out to 
be difficult. Further studies should be conducted to narrow down the domain of PMCA4 
implicated in the interaction with calcineurin to the minimal size. This information might 
lead to the design of small cell-penetrating peptides, based on this small fragment of 
PMCA4, that would enter the endothelial cells and disrupt the interaction with 
calcineurin.     
In this thesis I have also demonstrated that inhibition of the calcium-extrusion function of 
PMCA4 has a different effect on the interaction of the pump with calcineurin or eNOS. In 
fact, whereas inhibition of PMCA4 with ATA enhances angiogenic processes, ATA 
attenuates VEGF-induced synthesis of nitric oxide. Therefore, together with the 
characterisation of the molecular nature of the PMCA4/calcineurin interaction, further 
analysis of the PMCA4/ eNOS interaction is also warranted. Particular attention should 
be paid to the role play by calcium in the interaction of PMCA4 with these two partner 
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proteins. Inhibition of PMCA4 calcium extrusion with ATA is expected to increase the 
concentration of intracellular calcium in the vicinity of PMCA4. Work performed by other 
laboratories in human sperm has shown that the interaction between PMCA4 and eNOS 
increases with elevation of intracellular calcium. This might explain our observation 
showing increased interaction between PMCA4 and eNOS in endothelial cells treated 
with ATA. 
Given the critical relevance of nitric oxide synthesis by endothelial cells in the control of 
vascular tone, future therapeutic interventions based on PMCA4 inhibition might have 
undesired hypertensive side-effects. For this reason, the characterisation of the 
molecular nature of the interaction of PMCA4 with calcineurin and eNOS is essential to 
the future development of efficient therapeutic strategies. Moreover, although both 
proteins have been reported to interact with the domain 428-651 of PMCA4, this is a 
very big domain. Therefore, together with the identification of the minimal domain of 
PMCA4 that interacts with calcineurin, it will also be highly interesting to determine the 
minimal region of PMCA4 that interacts with eNOS. If minimal interaction domains with 
the two partner proteins are different, this information could be used to disrupt the 
interaction PMCA4/calcineurin without affecting to the interaction PMCA4/eNOS and 
thus without modifying the influences of PMCA4 on nitric oxide production.  
All these possibilities deserve further investigation.        
5.3 Limitations of the study 
Given the context of the target disease in this study, HUVEC cells were used as an in 
vitro model to study angiogenesis. HUVEC cells are a widely used, robust cell model to 
study molecular mechanisms of endothelial cell function (Staton et al., 2009). If time 
permitted, the effect of ATA should have been further validated in different vascular 
beds using other arterial cells such as Human Cardiac Microvascular Endothelial cells 
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(HCMEC), Human Aortic Endothelial cells (HAoEC), Human Coronary Artery 
Endothelial cells (HCAEC), etc. 
Another interesting point to consider is that the western blot data presented in figure 
4.4.2.2 shows several bands. The size of these bands (around 138 kDa) is in 
agreement with size reported for PMCA4, furthermore, there is no detection of any of 
these bands in protein extracts isolated from PMCA4 knockout mice, thus confirming 
the specificity of the antibody for detection of PMCA4. The presence of 3 different bands 
is not clear at present. Even when we have used protease inhibitors for processing the 
samples, the different bands could represent degradation products from the full length 
protein. Alternatively, these bands might be the result of alternatively spliced versions of 
PMCA4. As previously mentioned, RNA alternative splicing at site A and C generates 
huge PMCA isoform diversity. To date more than 20 varieties of PMCAs have been 
reported (Strehler and Zacharias., 2001). Therefore, it would be very interesting to 
determine the exact involvement of different splice versions of PMCA4 in the regulation 
of calcineurin/NFAT pathway in the presence of ATA and consequently angiogenesis in 
endothelial cells. 
This study has established proof-of-concept on the potential therapeutic value of 
targeting endothelial PMCA4 to promote blood vessel formation in patients suffering 
from cardiovascular ischemic disease characterised by insufficient angiogenesis. Since 
therapeutic angiogenesis will be required in ischemic disease, endothelial cell activation 
and effect of ATA under hypoxic condition need to be performed. Further study into the 
role of PMCA4 and ATA in the regulation of signalling pathways under hypoxic 
condition, provides a potential therapeutic value for the regulation of pathological 
angiogenesis.  
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Concluding Remarks 
- This work has established proof-of-concept on the potential therapeutic value of 
targeting endothelial PMCA4 to promote blood vessel formation in patients 
suffering from cardiovascular diseases characterised by insufficient 
angiogenesis.  
- Inhibition of PMCA4 calcium extrusion activity in endothelial cells with low doses 
of the small molecule aurintricarboxylic acid (ATA) enhances VEGF-induced 
angiogenic processes such as endothelial cell motility and tubular 
morphogenesis.  
- High concentrations of ATA administered for prolonged periods reduce 
endothelial cell viability and impair tube formation, suggesting that at its present 
formulation ATA is unlikely to be suitable for clinical use. Refined, less-toxic 
versions of ATA or the identification of novel, more specific inhibitors of PMCA4 
would be required in therapeutic clinical interventions.   
- ATA enhances the VEGF-induced activity of the calcineurin/NFAT pathway 
through disruption of the interaction between PMCA4 and calcineurin at the 
endothelial cell membrane. Our results indicate that novel therapeutic strategies 
based on the disruption of the PMCA4/calcineurin interaction in endothelial cells 
might have an important clinical value to improve blood vessel formation in the 
ischaemic tissues of patients with cardiovascular ischaemic disease.   
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APPENDIX 1 Table of stacking and resolving gel preparation for western blot 
analysis 
 
 
Stacking Gel 
Stacking buffer (0.5 M Tris-HCl, 0.4% SDS, pH6.6) (GENEFLOW, 
UK) Ultra Pure ProtoGel®  30% (w/v)  
 2.5 ml            
Acrylamide: 0.8% (w/v) Bis-Acrylamide (37.5:1)    
(acrylamide/bis-acrylamide) (GENEFLOW, UK)  
 1.4 ml 
dH2O   6.1 ml 
10% ammonium persulfate (APS)   100 µl 
N,N,N',N'-Tetramethylethylenediamine (TEMED)   80 µl 
 
      Resolving Gel Solutions 
Percentage of gels 
6% 8% 10% 12% 
Ultra Pure ProtoGel®  30% (w/v) 
Acrylamide: 0.8% (w/v) Bis-Acrylamide 
(37.5:1)(GENEFLOW, UK) (ml) 
 
2.80 ml 
 
 
 
3.80 ml 
 
 
 
4.70 ml 
 
 
 
5.60 ml 
 
 
10x resolving buffer 
(4x 1.5 M Tris-HCl, 0.4% SDS, pH8.8) 
(GENEFLOW, UK)  (ml) 
 
3.70 ml 
 
 
 
3.75 ml 
 
 
 
3.75 ml 
 
 
 
3.75 ml 
 
 
10% ammonium persulphate (µl) 100µl 100 µl 100 µl 100 µl 
H2O (ml) 7.35 ml 6.4 ml 5.45 ml 4.55 ml 
N,N,N',N'-Tetramethylethylenediamine 
(TEMED) 
  80 µl   80 µl   80 µl   80 µl 
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APPENDIX 2 Table of primary antibodies used for western blot analysis 
 
Primary antibody 
specific for 
Type of antibody Host Dilution Supplier 
DSCR1 (RCAN1.4) Polyclonal Rabbit 1:1000 Sigma-Aldrich, UK 
Calcineurin- A (CnA) Monoclonal Mouse 1:1000 
BD Transduction 
Laboratories 
PMCA4 (JA3) Monoclonal Mouse 1:500 
Santa Cruz 
Biotechnology 
Tubulin Monoclonal Mouse 1:2500 Sigma-Aldrich, UK 
Pan cadherin Polyclonal Rabbit 1:4000 Abcam 
eNOS total Polyclonal mouse 1:10000 Sigma-Aldrich, UK 
Erk 1/2 Polyclonal Rabbit 1:1000 
Cell Signalling 
Technology 
p-Erk 1/2 Polyclonal Rabbit 1:1000 
Cell Signalling 
Technology 
Flag epitope (M2 
peroxidase HRP-
conjugated) Monoclonal   1:2000 Sigma-Aldrich, UK 
Secondary antibody Dilution Supplier 
ECLTM Anti-Rabit IgG- Horseradish peroxidase 1:5000 GE Healthcare, UK 
ECLTM Anti-Mouse IgG- Horseradish peroxidase 1:5000 Sigma-Aldrich, UK 
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APPENDIX 3 Experiments performed by our collaborators related to the study 
presented in this thesis 
 
 
 
Figure Appendix 3A Administration of ATA at low concentrations boosts post-ischaemic 
hind limb perfusion in mice. Representative laser Doppler images showing blood flow at 4 
days after surgery in sham-operated non-ischaemic legs (S) and femoral-ligated ischaemic legs 
(I) of mice receiving ATA (5 mg/kg/day) or vehicle (DMSO) by intraperitoneal injection. 
Histograms show data as mean ±SE, n=7, obtained from 2 independent experiments. **denotes 
statistically significant differences (P≤0.01, according to unpaired, two-tailed Student t test) in 
blood flow in the ischaemic leg of mice receiving ATA vs vehicle. ns=non-significant.  
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Figure Appendix 3B ATA treatment is toxic to zebrafish embryos at concentrations over 
100 μM. Zebrafish Tg(kdrl:HRAS-mCherry; flk1:EGFP-nls) dechorionated embryos were 
incubated for 24 hours with increasing concentrations of the selective PMCA4 inhibitor ATA or 
vehicle (DMS0) from 30 hours post fertilisation (hpf). Vascular morphology was imaged at 54 
hpf using a Zeiss Lightsheet Z.1 microscope. Images show vascular morphology in embryos 
treated with100 μM ATA or DMSO. Membrane-tagged endothelial mCherry (red). Endothelial 
cell nuclei (green). Histogram shows embryo viability 24 hours after treatment. Results are 
representative of 2 independent experiments. 
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APPENDIX 4 Determination of adenovirus plaque forming units 
Dilutions PFU/mL Dilutions PFU/mL 
10-2 1 x 103 7.81 x 10-9 1.28 x 109 
10-3 1 x 104 3.91 x 10-9 2.56 x 109 
10-4 1 x 105 1.95 x 10-9 5.12 x 109 
10-5 1 x 106 9.77 x 10-10 1.02 x 1010 
10-6 1 x 107 4.88 x 10-10 2.05 x 1010 
5 x 10-7 2 x 107 2.44 x 10-10 4.1 x 1010 
2.5 x 10-7 4 x 107 1.22 x 10-10 8.19 x 1010 
1.25 x 10-7 8 x 107 6.1 x 10-11 1.64 x 1011 
6.25 x 10-8 1.6 x 108 3.05 x 10-11 3.28 x 1011 
3.12 x 10-8 3.2 x 108 1.53 x 10-11 6.55 x 1011 
1.56 x 10-8 6.4 x 108 7.63 x 10-12 1.31 x 1012 
 
 
 
 
 
 
 
 
 
156 
 
APPENDIX 5A Western blot images and the antibodies employed in these studies 
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APPENDIX 5B Western blot images and the antibodies employed in these studies 
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